BONE CANONICAL WNT/B-CATENIN SIGNALING IN MODELS OF REDUCED MICROGRAVITY

A Dissertation

by

BRANDON RICHARD MACIAS

Submitted to the Office of Graduate Studies of Texas A&M University in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY

Approved by:

Chair of Committee, Susan A. Bloomfield
Committee Members, Harry A. Hogan
                      Michael Massett
                      John Ford
Head of Department, Richard Kreider

December 2012

Major Subject: Kinesiology

Copyright 2012 Brandon Richard Macias
ABSTRACT

Human exposure to reduced weightbearing results in bone loss. The rate of bone loss during microgravity exposure is similar to that of a post-menopausal women. In fact, the maintenance of bone mass is intimately dependent on exercise. Therefore, exercise associated mechanical loads to bone tissue are an important countermeasure to prevent disuse-induced bone loss. However, the types of exercise modalities required to prevent such bone loss are unclear. Moreover, how mechanical loading to bone translates into molecular osteogenic signals in bone cells is unknown. Radiation exposure is another potent inducer of bone loss, namely observed on Earth in the clinical setting following radiotherapy procedures. It is expected that long duration space missions outside the protection of Earth’s magnetosphere will result in significant galactic cosmic radiation exposure. However, the magnitude of bone loss resulting from this galactic cosmic radiation exposure is unclear. Moreover, it is unknown if radiation exposure will exacerbate disuse-induced bone loss. Therefore, a series of experiments were designed to determine: 1) Will simulated galactic cosmic radiation exacerbate reduced weightbearing-induced bone loss? 2) Will pharmacological activation of the putative mechanosensing Wnt pathway enhance exercise-induced bone mass gain? To address these questions the experimental study series employed two animal models of reduced weightbearing, hindlimb unloading and partial weightbearing. These model test-beds enabled the evaluation of two novel countermeasures (simulated resistance exercise and glycogen synthase kinase-3 (GSK-3) therapeutic) and simulated exposure to
space radiation environments. To test the impact of simulated space radiation (\textsuperscript{28}Si) one study of the series was conducted at Brookhaven National Laboratory. To quantify the impact of the abovementioned countermeasures and space radiation on bone, mechanical testing, peripheral quantitative computed tomography, micro-computed tomography, histomorphometry, and immunohistochemistry served as primary outcome measures.

The primary findings are: 1) Low-dose high-LET radiation negativity impacts maintenance of bone mass by lowering bone formation and increasing bone resorption. This impaired bone formation response is in part due to sclerostin induced suppression of Wnt signaling. 2) Combining GSK-3 inhibition with high intensity exercise mitigates cancellous bone loss and restores cortical periosteal growth during disuse.
ACKNOWLEDGEMENTS

HaOne, Mom, Dad, and Nana, thank you for the enduring love and support. Thank you to Drs. Susan Bloomfield and Alan Hargens for the many years of support and helping to make so many opportunities a reality. To my committee members, thank you for your support and guidance. JM Swift’s invaluable training provided an excellent foundation for work in the Bone Biology Laboratory. In addition, great appreciation to all the students who helped make these labor intensive animal studies a reality.

It should be noted that the article titled, “Simulated resistance training, but not alendronate, increases cortical bone formation and suppresses sclerostin during disuse,” that appears as Appendix A presents work of a collaborative effort by JM Swift, MI, Nilsson, HA Hogan, SD Bouse, and SA Bloomfield (Macias BR, Swift JM, Nilsson MI, Hogan HA, Bouse SD, Bloomfield SA. Simulated resistance training, but not alendronate, increases cortical bone formation and suppresses sclerostin during disuse. J Appl Physiol 112:918-925, 2012). Without their major contributions, this labor intensive study would not have been possible. Beyond, dynamic histomorphometry analysis, statistical analysis, interpretation, and writing this published work, BR Macias major contribution to this work was employment of the sclerostin immunohistochemistry assay.

Thank you to the outstanding funding institutions for supporting graduate student research and education:
Texas A&M Space Life Science Graduate Student Training Program funded by
the National Space Biomedical Research Institute (NASA NCC 9-58)
National Science Foundation (NSF) Graduate Research Fellowship Program
Nordic Research Opportunity made possible by the NSF, Swedish Research
Council, and the Laboratory of Professor Per Aspenberg.
Texas A&M University Office of Graduate Studies
Texas A&M Association of Former Students
Huffines Institute for Sports Medicine and Human Performance
American College of Sports Medicine’s NASA Space Physiology Grant
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSTRACT</td>
<td>ii</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>iv</td>
</tr>
<tr>
<td>TABLE OF CONTENTS</td>
<td>vi</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td>viii</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>ix</td>
</tr>
<tr>
<td>CHAPTER</td>
<td></td>
</tr>
<tr>
<td>I  INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td>II LITERATURE REVIEW</td>
<td>4</td>
</tr>
<tr>
<td>Bone Remodeling and Modeling</td>
<td>4</td>
</tr>
<tr>
<td>Osteocyte Control of Bone Remodeling</td>
<td>5</td>
</tr>
<tr>
<td>Bisphosphonates</td>
<td>5</td>
</tr>
<tr>
<td>Wnt Signaling in Bone Tissue</td>
<td>6</td>
</tr>
<tr>
<td>Interleukin-6 (IL-6) in Wnt Signaling</td>
<td>8</td>
</tr>
<tr>
<td>SOST and Sclerostin Expression in Wnt Signaling</td>
<td>9</td>
</tr>
<tr>
<td>Pharmacological Intervention via Wnt/β-catenin (canonical) Signaling</td>
<td>10</td>
</tr>
<tr>
<td>Wnt Signaling Activators</td>
<td>11</td>
</tr>
<tr>
<td>Space Radiation Environment</td>
<td>12</td>
</tr>
<tr>
<td>Radiation Induced Bone Loss and Fractures</td>
<td>13</td>
</tr>
<tr>
<td>Exercise Countermeasures for Humans during Spaceflight</td>
<td>13</td>
</tr>
<tr>
<td>Exercise Countermeasures in Ground-Based Rodent Models</td>
<td>14</td>
</tr>
<tr>
<td>III SIMULATING THE LUNAR ENVIRONMENT: PARTIAL WEIGHTBEARING AND HIGH-LET RADIATION INDUCES BONE LOSS AND INCREASED SCLEROSTIN-POSITIVE OSTEOCYTES</td>
<td>17</td>
</tr>
<tr>
<td>Introduction</td>
<td>17</td>
</tr>
<tr>
<td>Materials and Methods</td>
<td>20</td>
</tr>
<tr>
<td>Results</td>
<td>27</td>
</tr>
</tbody>
</table>
LIST OF TABLES

Table 1  Proximal Tibia Morphometry ............................................................... 54
Table 2  Cortical Midshaft Tibia Bone Morphometry ................................. 57
## LIST OF FIGURES

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1</td>
<td>Mechanotransduction via Wnt/β-catenin (canonical) pathway in an osteoblast</td>
<td>7</td>
</tr>
<tr>
<td>Figure 2</td>
<td>Dkk-1 and TNF-α inhibition of mechanotransduction via the Wnt/β-catenin pathway in an osteoblast</td>
<td>9</td>
</tr>
<tr>
<td>Figure 3</td>
<td>Molecular structure of (2'Z,3'E)-6-Bromoindirubin-3'-oxime, BIO, a potent and selective, ATP-competitive glycogen synthase kinase-3 (GSK-3) inhibitor (95)</td>
<td>12</td>
</tr>
<tr>
<td>Figure 4</td>
<td>Simulated Resistance Training (SRT)</td>
<td>16</td>
</tr>
<tr>
<td>Figure 5</td>
<td>Effects of G/6 weightbearing and X-ray radiation exposure on body mass</td>
<td>27</td>
</tr>
<tr>
<td>Figure 6</td>
<td>Effects of G/6 weightbearing and $^{28}$Si radiation exposure on body mass</td>
<td>28</td>
</tr>
<tr>
<td>Figure 7</td>
<td>Cancellous microarchitecture during partial weightbearing and X-ray or $^{28}$Si exposure</td>
<td>29</td>
</tr>
<tr>
<td>Figure 8</td>
<td>Partial Weightbearing X-ray radiation, and $^{28}$Si radiation effects on midshaft femoral cortical geometry</td>
<td>31</td>
</tr>
<tr>
<td>Figure 9</td>
<td>Partial Weightbearing and radiation effects on femoral neck mechanical properties</td>
<td>32</td>
</tr>
<tr>
<td>Figure 10</td>
<td>Partial Weightbearing for 21-days and $^{28}$Si radiation exposure elevates serum TRAP 5b levels compared to 1G cage controls animals</td>
<td>33</td>
</tr>
<tr>
<td>Figure 11</td>
<td>Proportion of sclerostin positive osteocytes during partial weightbearing and radiation exposure</td>
<td>34</td>
</tr>
<tr>
<td>Figure 12</td>
<td>Partial Weightbearing and $^{28}$Si radiation effects on tibial cortical dynamic histomorphometry</td>
<td>35</td>
</tr>
<tr>
<td>Figure 13</td>
<td>Partial Weightbearing and X-ray radiation effects on tibial cortical dynamic histomorphometry</td>
<td>36</td>
</tr>
</tbody>
</table>
Figure 14  The highest acute $^{28}\text{Si}$ radiation dose during 1G raises lipid peroxidation levels in tibias after 21-days................................. 37

Figure 15  Effects of hindlimb unloading (HU) with or without GSK-3 (BIO) treatment and/or simulated resistance training (SRT) on cancellous bone microarchitecture.......................................................... 55

Figure 16  Effects of hindlimb unloading (HU) with or without GSK-3 (BIO) and/or simulated resistance training (SRT) on periosteal and endocortical surface dynamic histomorphometric analyses measured at the tibia diaphysis.......................................................... 58

Figure 17  Femoral neck bone mineral content and strength.......................... 59

Figure 18  Serum IL-6 after 28-days of disuse (HU+Vh) is significantly higher compared to those levels in full weight bearing controls................. 60
CHAPTER I
INTRODUCTION

Human exposure to reduced weightbearing results in bone loss. In fact, the maintenance of bone mass is intimately dependent on mechanical loading. Reduced weightbearing, for example during 6-month International Space Station (ISS) spaceflight missions (with moderate use of exercise equipment) results in 1-2% bone loss per month. The National Aeronautic and Space Administration (NASA) recognized the risk of microgravity-induced bone loss early in the space program’s history, prior to the existence of the ISS (69). Therefore, exercise countermeasures, human ground-based analogs, and ground-based animal models were developed to test countermeasures to mitigate bone loss during spaceflight. In the 1970’s a team of scientist at NASA-Ames research center developed a ground-based animal model to simulate the “microgravity” effects of reduced load bearing to bone and muscle. This model is now often referred to as the “Hindlimb Unloading,” (HU) model.

Exercise countermeasures have been employed early in the Space Program’s history, starting with the Gemini era. Skylab missions were equipped with a cycle ergometer, isokinetic rope-pull resistance exercise systems, and treadmill. Presently onboard the ISS, exercise countermeasures include treadmills, cycle ergometer, and high-force resistance exercise equipment. Both studies on the ground and in-flight indicate that high intensity resistance exercise is required to generate an anabolic response in bone. In summary, bone is a dynamic tissue responsive to reduced and
increased levels of load. Bone tissue is of critical importance for the maintenance of ambulatory function. Moreover, the skeleton functions as a mineral reservoir for basic physiological cellular function and physiological fluid homeostasis. Beyond broken bones or altered gait, the loss of bone tissue and/or imbalance in bone turnover can negatively affect other physiological systems, for example, muscle cell contractility, kidney function, or neurological function.

Human exploration of the moon, Mars, or even distant planetary bodies, such as, asteroids will expose astronauts to galactic cosmic radiation (GCR). The estimated high-linear energy transfer radiation dose for a Mars mission is approximately 0.4 to 0.5 Gy (19). GCR includes but is not limited to high-energy heavy ions, characterized by high charge and energy (19). Data on the biological effect of high-energy heavy ions is limited; furthermore, a possible synergistic interaction between radiation and microgravity-induced physiological deconditioning (including but not limited to deconditioning of bone matrix, bone cells, and bone progenitor cells) is unknown. The effects of radiation on biological systems are complex and to date there are no human data that document the risk to GCR exposure (31). Ground based research models of GCR in bone with high dose X-ray irradiation (15-30 Gy) have shown deleterious effects on bone. While these studies provide invaluable data, at present there are few data reporting the effect ionizing radiation on bone.

The development of exercise and pharmaceutical countermeasures to mitigate disuse- and radiation-induced bone loss is of critical importance for the realization of long duration human exploration class missions. The two experiments presented herein
were designed to test exercise and/or pharmaceutical countermeasures for bone loss using animal ground-based models of microgravity. A second objective was to employ a new murine model of reduced weightbearing, to determine if radiation exposure would exacerbate bone loss during simulated Lunar gravity. Given that the bone matrix embedded osteocyte is the putative mechaoregulator cell in bone, these studies sought to determine how cortical sclerostin-osteocyte levels respond to unloading and radiation exposure. These experiments are the first to investigate the combined effects of 1) Partial weightbearing and radiation exposure, and 2) Simulated resistance exercise and pharmacological activation of Wnt signaling during disuse.
CHAPTER II
LITERATURE REVIEW

Bone Remodeling and Modeling

Osteoblasts are the basic bone forming cell and osteoclasts are the basic bone resorbing cell (70). During bone remodeling osteoblasts can become embedded in the organic bone matrix. Once embedded these osteoblasts often terminally differentiate into mature osteocytes. Osteoblasts derive from the mesenchymal cell lineage, while osteoclasts derive from the hematopoietic cell lineage. Osteoclasts and osteoblasts form the basic multicellular unit (BMU) that actively remodels the skeleton throughout life. Osteoclasts function on bone surfaces to resorb bone, facilitating repair of weak bone sites and/or liberating minerals, such as calcium. These osteoclasts working on bone surfaces are often followed by a “team” of osteoblasts laying down osteoid (new bone matrix). An imbalance in bone turnover, for example, an excess of osteoclast activity, can result in bone loss. Alternatively, more vigorous osteoblast activity than resorbing osteoclasts can result in net bone gain. Osteoclasts present the protein Receptor Activator of Nuclear Factor κ B (RANK) to the cellular surface. Whereas, nearby osteoblasts present the membrane protein RANK-Ligand (RANK-L). Lower levels of RANK-L reduce osteoclastogenesis and induce osteoclast apoptosis. In addition, osteoblasts can secrete osteoprotegerin (OPG) that functions as a decoy receptor to bind to the RANK-L and interfere with RANK signaling. Thus, the OPG/RANK-L axis functions to couple osteoblast and osteoclast activity; in addition, the OPG:RANK-L
ratio functions as one important laboratory measures of bone turnover status. The uncoupled action of osteoblasts from osteoclasts is termed bone modeling. Modeling allows the deposition of new bone matrix without prior osteoclast bone resorption. Bone modeling occurs during skeletal growth and development. Bone modeling occurs less frequently in the adult skeleton. Mechanical loading of bone is one such stimulus capable of initiating bone modeling. Bone modeling occurs more frequently on cortical bone surfaces than cancellous bone surfaces.

**Osteocyte Control of Bone Remodeling**

Recent evidence suggests that osteocyte-secreted proteins regulate osteoblast proliferation, activity, and bone matrix synthesis. Osteocytes are the most abundant cell in bone tissue; however, less is known about osteocyte function (10:1, osteocyte: osteoblast) as compared to osteoclasts and osteoblasts. Recent osteocyte cell culture studies show that osteocytes secrete factors in response to mechanical and shear forces (10-12). Sclerostin is one such osteocyte-secreted factor that inhibits Wnt signaling, osteoblastogenesis, and thus results in reduced bone formation capacity. More recently, it has been demonstrated that osteocytes also secrete RANK-L, a key regulator of osteoclast maturation and activity (60,99). Taken together, these recent osteocyte biology developments suggest that osteocytes are the key responders to mechanical loading and can regulate both bone formation and bone resorption activity.

**Bisphosphonates**

Bisphosphonates, such as alendronate, are now a Food and Drug Administration (FDA: Application No. NDA-020560) approved class of pharmaceuticals designed for
the treatment and prevention of post-menopausal osteoporosis in women, treatment of osteoporosis in men, treatment of glucocorticoid-induced osteoporosis in men and women, and treatment of Pagets’ disease. Bisphosphonates potently inhibit bone resorption and reduce fracture incidence (15,48). Currently, alendronate (oral dose of 70 mg of alendronate taken weekly starting 3 weeks prior to flight) is being administered to some astronauts in an ongoing experiment on the ISS to test its efficacy as a countermeasure for microgravity-induced bone loss. Several studies document the efficacy of alendronate to mitigate disuse-induced bone loss (3-4). The highly charged phosphate backbone within the bisphosphonate molecule provides a high affinity interaction with calcium hydroxyapatite bone surfaces. Therefore, during bone remodeling bisphosphonate coated bone surfaces reduce the incidence of osteoclast attachment to bone. These bisphosphonates become incorporated into the bone matrix. Moreover, osteoclast-digested bisphosphonates inhibit the mevalonate pathway, causing osteoclast detachment from the bone surface and in some cases apoptosis (68,89).

**Wnt Signaling in Bone Tissue**

Bone mass and architecture adapt to mechanical load; for example, when mechanical load is below the physiologic threshold (e.g., microgravity), bone is resorbed. Data published over the last ten years implicate the Wnt pathway in control of load-induced bone formation; however, the basic molecular mechanisms governing the osteogenic response to mechanical load are unknown. Loss-of-function mutation of the low-density lipoprotein receptor-related protein 5 (Lrp5) gene impairs response to mechanical load, decreases bone mass, and osteoblast proliferation (24). In contrast, a
gain-of-function mutation of Lrp5 that disrupts the binding site of sclerostin is associated with a high bone mass phenotype. The Wnt pathway coordinates communication between mechanosensing osteocytes (via secreted sclerostin) and bone-forming osteoblasts (Figure 1).

Interestingly, mechanical loading \textit{in vivo} down-regulates sclerostin (71) and up-regulates osteogenic gene expression. When mice lacking sclerostin are subjected to simulated microgravity, the Wnt pathway is unaffected and bone loss does not occur (47). However, it is unknown if \textit{in vivo} mechanical loading can overcome the potent stimulus of reduced weight bearing; furthermore, it is unknown if the Wnt pathway is active at graded levels of reduced weight bearing.
Interleukin-6 (IL-6) in Wnt Signaling

Data in the last ten years clearly demonstrates that Wnt signaling regulates osteoblast differentiation and bone accrual in adult vertebrates (human and rodent). Recently, cytokines such as tumor necrosis factor (TNF-α) and extracellular antagonists such as RANK-L, sclerostin and Dickkopf-1 (Dkk-1) have been shown to impair bone formation. This impairment may result in bone loss. It appears that these proteins disrupt mechanotransduction in bone by inhibiting Wnt-Ligand and LRP4/5/6 complex formation. Sclerostin and Dkk-1 are known potent inhibitors of Wnt signaling; \textit{in vitro} TNF-α has been shown to potentiate Dkk-1 inhibition of Wnt signaling (61). However, it is unclear how Dkk-1, TNF-α, and IL-6 interact to regulate bone formation and bone resorption (39). IL-6 is considered a potent osteoclastogenic cytokine (62). Primary cultures of bone cells from HU animals exhibit slowed osteoblast differentiation and higher IL-6 production compared to cage controls (25). Moreover, IL-6 has been show to increase RANK-L secretion in a paracine/autocrine manner (56). It appears that IL-6 expression in osteoblast is regulated by oxidized phospholipids (88). Interestingly, there is some evidence that reactive oxygen species are elevated in patients with osteoporosis (90) and that antioxidants provide some protection against disuse-induced bone resorption (77). Therefore, the interaction of Dkk-1, TNF-α, and IL-6 may be an important signaling complex that regulates bone formation and bone resorption (Figure 2).
Figure 2. Dkk-1 and TNF-α inhibition of mechanotransduction via the Wnt/β-catenin pathway in an osteoblast. Mechanical loading promotes formation of the Wnt-LRP5/6-Frizzled transmembrane complex and thus downstream intracellular signaling and gene expression. Wnt signaling diverts the mesenchymal stem cells down the pathway of osteoblast differentiation. Sclerostin and Dkk-1 are potent extracellular antagonists of Wnt signaling. Dkk-1 binds to the Wnt receptor complex on the surface of the osteoblast lineage cell and blocks Wnt signaling, arresting osteoblast proliferation and differentiation. Blockade of Dkk-1 or TNF-α permits progression of osteoblast differentiation.

SOST and Sclerostin Expression in Wnt Signaling

SOST gene expression is responsive to disuse. Unloading for 3 days in mice results in a significantly higher SOST gene expression in tibial bone homogenates (cortical, cancellous, and marrow) compared to normal cage controls (71). Conversely, externally applied mechanical loading of rodent bone produces an anabolic response and can lower SOST expression. For example, SOST gene expression is downregulated following repeated bouts of daily 3-minute loading cycles using the ulnar-loading model (53). Similarly, external mechanical loading of 11-wk old female C57/B6 mouse
tibias (peak strain of -1300 uE, 2Hz for 30sec) produces a 3-fold lower SOST expression (101).

SOST and sclerostin expression in response to mechanical loading may be bone-site specific. SOST expression levels are similar in cortical and cancellous bone at metaphyseal, epiphyseal, and diaphyseal sites (75). In addition, sciatic neurectomy-induced bone loss is accompanied by significantly higher numbers of sclerostin-positive osteocytes in both the primary and secondary spongiosa of metaphyseal bone (59). Interestingly, however, external axial loading of tibiae in neurectomized limbs (at 1800 uE) significantly lowers the proportion of sclerostin-positive osteocytes in the metaphyseal cortical bone but not midshaft cortical bone compared to ambulatory control mice (59). Those cortical bone regions exhibiting the largest increases in newly formed bone area also exhibit the greatest decreases in sclerostin-positive osteocytes of proximal tibias (59). Therefore, there may be important site-specific differences in how SOST and sclerostin expression respond to altered mechanical loading.

**Pharmacological Intervention via Wnt/β-catenin (canonical) Signaling**

Glycogen synthase kinase-3-beta (GSK-3β) is a key modulator of the Wnt signaling pathway. Therefore, GSK-3β is an attractive target of drug development to resolve metabolic and neurological diseases. Inhibition of GSK-3β can normalize blood glucose levels in an animal model (17) and suppress neuronal apoptosis (6). GSK-3β inhibitors have recently been used to activate Wnt signaling in bone cells and increase bone mass in various rodent models (38,54). GSK-3β inhibition prevents ovariectomy-induced femoral bone loss (38). Similarly, femoral cancellous and cortical BMD are
higher in normal healthy animals treated with a GSK-3β inhibitor (54). However, it is unknown whether inhibition of GSK-3β can mitigate bone loss during disuse or how GSK-3β inhibition interacts with increased mechanical loading.

**Wnt Signaling Activators**

More recently, a new class of pharmaceuticals is being tested and developed to target Wnt signaling in bone tissue. When activated, Wnt signaling initiates a profound increase in osteoblastogenesis, resulting bone mass gain. New antibody pharmaceuticals currently under development are designed to target Dkk-1 and Sclerostin (1,2,45,63). In addition, (Glycogen synthase kinase-3) GSK-3 inhibitors are being developed to target Wnt signaling. (2'Z,3'E)-6-Bromoindirubin-3′-oxime, also known as BIO, is a potent and selective inhibitor of the intracellular protein GSK-3 (Figure 3). GSK-3 inhibitors function by inhibiting GSK-3 dependent phosphorylation of beta-catenin. The lack of phosphorylation side chains on the beta-catenin protein prevents trafficking of beta-catenin to the proteosome for degradation. Thus, GSK-3 inhibition raises intracellular beta-catenin levels which can then cross the nuclear membrane to activate an osteogenic gene expression profile.
Space Radiation Environment

The space radiation environment is primarily composed of galactic cosmic radiation (GCR), solar particle events, and secondary radiation products. Ongoing advancements in solar storm monitoring, materials, and high velocity space vehicles will reduce the radiation risk to astronauts (51). However, despite expected future engineering advancements, crew members will accrue some low dose GCR exposure during exploration class missions. The GCR spectrum is low fluence and primarily composed of heavy charged particles (C through Fe) and protons. A 1000-day human exploration mission to Mars is expected to result in a total absorbed dose of about 0.42 Gy (19). A round trip 88-day mission to the moon would involve a total dose equivalent to the bone marrow of 0.074 Gy (26). Radiation risk models estimate a 4.2% (95% CI: 1.3-13.6) fatal risk for missions to Mars and for similar exploration class missions to
other distant objects. This estimated risk level violates the current 3% career limit for excess cancer mortality recommended by the [National Council on Radiation Protection] for space activities for both sexes and all ages (26). However, the radiation risk estimate for radiation-induced bone loss is unknown.

**Radiation Induced Bone Loss and Fractures**

Radiation exposure to bone tissue increases the risk of skeletal fracture; for example, pelvic fracture rate is two-fold higher after radiation therapy for anal cancer (5,7,65,67). In addition, radiation therapy early in life results in reduced bone density later in life (65). Therefore, dividing a large gamma or proton radiation dose into small fractions is a common therapeutic strategy to deliver a sufficient radiation dose (for example, 10-50 Gy) to pathological tissue while sparing neighboring healthy normal tissue (102). Similar fractionation strategies have been employed in ground based studies to test the effects of high-LET and low-fluence GCR that astronauts might experience on distant missions. Utilizing fractionated dose regimes may help better simulate the low dose rate exposures to GCR during sojourns in space.

**Exercise Countermeasures for Humans during Spaceflight**

Current exercise hardware and exercise prescriptions performed during ISS missions (~6 months) do not completely prevent musculoskeletal deconditioning, but may mitigate some of the musculoskeletal loss (42,73,76,78-79,81,87). Recent data show that when exercise on the advanced resistive exercise device (aRED) is combined with adequate nutrition, astronauts exhibit no net bone loss after 6 month ISS missions at most bone sites (76). However, it is unclear how these DEXA derived measures of bone
mass translate into mitigation of bone strength loss following 6-month ISS missions. These human exercise evaluations during microgravity provide further evidence that high impact resistive exercise prescriptions are necessary to prevent bone loss during long duration space missions.

**Exercise Countermeasures in Ground-Based Rodent Models**

The rodent hindlimb unloading (HU) model is a well-established ground-based model for investigating disuse effects on bone (58,72,91,93). Our recent publication details how high intensity muscle contractions at 75-to-100% peak isometric torque (P₀), produced during simulated resistance training (SRT) (Figure 4) which is undertaken during a period of HU, produce significant gains in proximal tibia cancellous and mid-diaphyseal tibia cortical bone (50,83). These gains were associated with a significantly greater bone formation rate (BFR) as compared to control animals (50,83). Therefore, high intensity exercise provides some protection against disuse-induced bone loss in rodent ground-based simulations of microgravity. In fact, SRT produces bone mass gains during HU for several key bone measures.

Mechanical loading, SRT, during disuse dampens sclerostin secretion from osteocytes, resulting in Wnt signaling activation and bone gain (50). When the hindlimbs of rats are subjected to HU, sclerostin-positive osteocytes are significantly increased (50). However, when HU rats are subjected to SRT the number of sclerostin positive osteocytes are similar to weightbearing controls. The reduction of the number of sclerostin positive osteocytes by mechanical loading may explain the recovery of the normal bone mineral accretion during disuse (50). Therefore, these data suggest that
osteocytes embedded in bone matrix monitor the mechanical environment and respond by altering sclerostin protein levels.

During bone deposition some osteoblasts become embedded in bone matrix, when this occurs these cells are called osteocytes. Visual inspection of newly embedded osteocytes on the periosteal rim show very low sclerostin staining (50). This observation is consistent with previous reports (59). In fact, gene expression profile of newly embedded osteocytes is different from more mature osteocytes (70). Taken together, these data suggest that newly embedded osteocytes are genetically programmed to limit sclerostin production or local signaling inhibits sclerostin expression.

Sclerostin is a potent inhibitor of Wnt signaling in osteoblasts. HU effectively increases sclerostin levels and added SRT lowers the number of sclerostin-positive osteocytes (50). SRT imposed every third day during HU and prevents higher numbers of sclerostin-positive osteocytes (50). These data suggest high intensity exercise every third day provides a sufficient mechanical stimulus to reduce sclerostin levels and activate Wnt signaling.
Figure 4. Simulated Resistance Training (SRT). Isometric plus eccentric exercise using percutaneous of sciatic nerve to produce active plantarflexor muscle contractions at 75% of peak isometric torque. The Force instrumented servo-motor and footplate enable isometric and eccentric muscle contractions and simultaneous force measurements.

The ground-based tail suspension rodent hindlimb unloading model effectively reproduces the suppressed bone formation and increased bone resorption observed during spaceflight missions (57-58). However, the HU model requires the rodent be suspended at a 30° angle to appropriately load the tail and forelimbs, and to simulate a head-ward fluid shift (29). A novel harnessed mouse model has been developed for ground-based studies for the precise titration of ground reaction forces to all four limbs in order to study partial weightbearing effects (94). Three weeks of partial weightbearing at ~38% total body weight results in approximately a 26% reduction in cancellous BV/TV and 20% reductions in diaphyseal cortical thickness relative to full weightbearing controls (21,94).
CHAPTER III
SIMULATING THE LUNAR ENVIRONMENT: PARTIAL WEIGHTBEARING AND HIGH-LET RADIATION INDUCES BONE LOSS AND INCREASED SCLEROSTIN-POSITIVE OSTEOCYTES

Introduction

Human exposure to reduced weightbearing and radiation independently result in bone loss, however it was unclear if these two factors interact to exacerbate bone loss. Maintenance of bone mass is intimately dependent on mechanical loading. Reduced weightbearing, for example during 6-month International Space Station (ISS) spaceflight missions, results in 1-2% bone loss per month relative to preflight baseline values at the femoral neck and lumbar spine (40-41,92). In addition, radiation exposure early in life lowers bone mineral density later in life (65). Long duration human spaceflight missions outside the protection of Earth’s magnetosphere will result in low-dose radiation exposure (19). Therefore, the lack of weightbearing during spaceflight and space-radiation exposure present serious skeletal tissue degenerative health risks for astronauts on long duration exploration class missions. Moreover, it remains unclear how reduced weightbearing and added radiation exposure may impact bone mass on long duration space missions.

The magnitude of BMD loss and adaptations in bone geometry during a 6-month ISS mission produces declines in estimated bone strength equivalent to the median lifetime loss of that observed for Caucasian women (35). Of particular concern are high-
risk fracture sites such as the femoral neck and lumbar vertebrae. These skeletal sites are composed of a thin cortical shell and reduction in mass of the shell and cancellous core can increase the risk of fracture. Approximately 3 years, 6-times the typical ISS mission period, may be required to recover both mass and estimated strength to some of these skeletal sites (74).

The space radiation environment is primarily composed of galactic cosmic radiation (GCR), radiation emitted from solar particle events, and secondary radiation products (31). Ongoing advancements in radiation biology and engineering research will help reduce the radiation risk to astronauts. The GCR profile is of low-dose rate and primarily composed of heavy charged particles (C through Fe) and protons (hydrogen), and helium (31). A 1000-day human exploration mission to Mars is expected to result in total absorbed dose of about 0.42 Gy (19). A round trip 88-day mission to the moon would involve a total dose equivalent to the bone marrow of 74 mSv (26). Therefore, more data on radiation-induced bone loss are required to reduce the large uncertainties in estimates of radiation quality and to improve radiation risk estimates for exploration class missions.

Simulated GCR exposure of rodents provides the only experimental method to study the tissue level effects of low-dose high-linear energy transfer (LET) radiation. LET is the average local energy deposition per unit length of distance traveled in a material. GCR is primarily composed of high-LET radiation, radiation that is highly energetic and extremely penetrating. Radiation exposure to mice can independently induce potent cancellous bone loss and bone resorption (36,97). In fact, gamma
radiation doses as low as 1 Gy of can cause significant murine cancellous bone mass loss within 1-wk following radiation exposure (36). However, it remains less clear if low-dose high-LET radiation, a radiation species not typically encountered on Earth, cause similar levels of bone loss.

The ground-based tail suspension rodent hindlimb unloading (HU) model effectively reproduces the suppressed bone formation and increased bone resorption observed during spaceflight missions (57-58). The HU model requires the rodent be suspended at a 30° angle to appropriately load the tail and forelimbs and simulate the head-ward fluid shift (29). A new harness suspension mouse model has been developed for ground-based studies for the precise titration of ground reaction forces to all four limbs (94). Partial weightbearing at ~38% shows approximately a 26% reduction in cancellous BV/TV and 20% reductions in diaphyseal cortical thickness relative to full weightbearing controls (21,94).

The aim of this experiment was to simulate the partial weightbearing conditions and radiation environment on the Lunar surface. The experimental design employed both X-ray reference radiation and $^{28}$Si radiation to determine the radiation quality effect of high LET species on bone tissue. In addition, we employed a fractionated dose group to simulate the low-dose received over the course of an extended deep space mission. We hypothesized that simulated galactic cosmic radiation would exacerbate bone loss observed after reduced $1/6^{th}$ partial weightbearing and fractionation of the highest dose group would mitigate detrimental effects observed with one acute dose.
Materials and Methods

Animals

This study was approved by Texas A&M University’s Institutional Animal Use and Care Committee (IACUC) and Brookhaven National Laboratory (BNL) IACUC. Radiation doses used in this study were chosen to ensure sufficient probability that each cell would be exposed to one $^{28}\text{Si}$ particle and thus the X-ray energy equivalent was used.

X-Ray Experiment

Four-month old female BALB/cBYJ mice (Stock# 001026, Jackson Laboratories, Bar Harbor, Maine) were rank ordered by body weight and block assigned to one of 6 groups: (1) normal ambulatory cage control or 1 gravity group (1G SHAM, n=10), (2) 1G plus exposure to a fractionated 0.33 Gy X-ray dose (1G 3F x 0.33 Gy, n=10), (3) 1G plus exposure to a single 1 Gy dose (1G 1 Gy, n=10), (4) 1/6th weight bearing (G/6) group to simulate Lunar gravity (G/6 SHAM, n=12, (5) G/6 plus exposure to a fractionated 0.33 Gy X-ray dose (G/6 3F x 0.33 Gy, n=13), (6) G/6 plus exposure to a single 1Gy dose (G/6 1 Gy, n=14). The single acute 1 Gy dose was given on Day 0; the fractionated 0.33 Gy X-ray dose was given on Days 0, 7, and 14. Sham exposed mice were treated in the same manner as those exposed mice but without radiation exposure. The dose-rate for these X-rays exposures was 0.191 Gy/min (Norelco MG300 X-ray industrial radiograph). Animals were irradiated prior to suspension on Day 0. At the A&M radiation laboratory mice were placed in a plastic box at the center of the beam. No anesthesia was used on Day 0 exposures. Animals in the fractionated dose
group (3F x 0.33 Gy) were anesthetized on Day 7 and 14 (ketamine100mg/kg + xylazine 10mg/kg) before leaving the vivarium to limit any ambulatory activity during the transportation and irradiation periods. Suspended mice were anesthetized but remained in suspension. All animals were given a subcutaneous injection of saline (0.25ml) to prevent dehydration.

28Si Experiment

Four-month old female BALB/cBYJ mice (Jackson Laboratories, Bar Harbor, Maine) were ranked ordered by body weight and block assigned to one of 8 groups: (1) normal ambulatory cage control or 1 gravity group (1G SHAM, n=8), (2) 1G plus exposure to a single 0.17 Gy dose (1G 0.17 Gy, n=8) (3) 1G plus exposure to a fractionated 0.17 Gy 28Si dose (1G 3F x 0.17 Gy, n=7), (4) 1G plus exposure to a single 0.5 Gy dose (1G 0.5 Gy, n=8), (5) 1/6th weight bearing group to simulate Lunar gravity (G/6 SHAM, n=11), (6) G/6 plus exposure to a single 0.17 Gy dose (G/6 0.17 Gy, n=9), (7) G/6 plus exposure to a fractionated 0.17 Gy 28Si dose (G/6 3F x 0.17 Gy, n=11), (8) G/6 plus exposure to a single 0.5 Gy dose (G/6 0.5 Gy, n=10). The fractionated 0.17 Gy 28Si dose was given on Days 0, 2, and 7. The single acute 0.5 Gy 28Si dose was given on Day 0. The dose-rate for these radiation exposures was 0.25 Gy/min. The sham mice were treated similarly as the irradiate mice and positioned in the beam line but without radiation exposure. Due to logistical constraints at the NASA Space Radiation Laboratory (NSRL) the fractionated dose schedule differed from the X-ray experiment (Days 0, 7, and 14 versus Days 0, 2, and 7). All mice were placed in special 50ml conical tube foam rack system for sham and irradiation exposures. Animals in the
fractionated dose group (3F x 0.17 Gy) were anesthetized on Day 2 and 7 (ketamine100mg/kg + xylazine 10mg/kg) before placement into the tube/rack system to prevent ambulatory activity during irradiation.

For both experiments, the mice were acclimated for one week with standard conditions of temperature (23 ± 2°C) and light-controlled environment (12-hr light/dark cycle) and single-housed for two weeks prior to the experiment in cages with removable polypropylene perforated floors. Food (standard rodent chow, Harlan Teklad 8604) and water were available ad libitum. All animals were monitored for health and body weight was recorded daily.

For both experiments, animals were anesthetized with a ketamine:xylazine cocktail before euthanasia on day 21. To ensure the animals limbs did not bear weight to limbs prior to termination, all G/6 animals were anesthetized before removal from the suspension apparatus. Immediately after euthanasia cocktail injections, blood was collected via cardiac puncture, clotted and spun down to isolate serum. Following blood collection, animals were euthanized by decapitation and both femora and tibiae were harvested, stripped of soft tissue, and stored in either 70% ethanol at 4°C for micro computed tomography (µCT), histomorphometric analyses, wrapped in PBS-soaked gauze immediately and stored at −30°C for mechanical testing or snap frozen in liquid nitrogen and stored at -80°C for later determination of lipid peroxidation products.

Suspension Devices

Custom built mouse polycarbonate suspension cages (13” x 13” x 13”) with removable polypropylene perforated floors were used in this experiment. The
suspension system was composed of a stainless steel rod, plastic pulley, i-hook, and spring. This suspension system was modeled after that designed and tested previously to provide easy access to food and water but prevent animals from resting against the cage walls (94).

A specialized weighing apparatus was built to allow accurate measurement of total body mass over the course of the experimental protocol and allow for 1/6\textsuperscript{th} weightbearing titrations as described previously (94). This custom precision engineered weighing apparatus was built around an electronic scale (Ohaus Corp., Pine Brook, NJ) for daily weighing of all mice while suspended in its suspension harness. Small adjustments to the i-hook screw and spring suspension system were made to maintain 1/6\textsuperscript{th} weightbearing over the course of the study. A more detailed overview of this suspension and weighing system has been previously described (94).

*Micro-computed Tomography (\(\mu\)CT)*

Right distal femurs were scanned *ex vivo* with microcomputed tomography (\(\mu\)CT SkyScan 1172; SkyScan, Kontich, Belgium) to quantify 2D and 3D micro architecture. A 60kV X-ray source was used over an angular range of 180° with 0.70° rotational steps. [Note: These \(\mu\)CT scans and reconstructions were performed in a colleague’s laboratory (MR Allen, Indiana University School of Medicine, Indianapolis). Data reduction, statistical analysis, and interpretation of the results were performed by BR Macias.] Six micrometer resolution projection images generated, reconstructed and analyzed (NRecon and CTAn; SkyScan). For cancellous bone measurements, a 1mm segment within the distal metaphysis secondary spongiosa was identified and manually
traced. To distinguish between bone from soft tissue a threshold was applied (range, 100 to 255), and specimen analyzed in 3D for bone volume/ trabecular volume (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th). One slice, 3 mm proximal to the most distal end of the metaphyseal segment was analyzed to determine cortical bone area (Ct.Ar), polar moment of inertia (J), and Ct.Th. All nomenclature used follows those guidelines established for micro-computed tomographic evaluation of bone (13).

Cortical Dynamic Histomorphometry Analysis

Intraperitoneal injections of calcein (Sigma Chemical, St. Louis, 15 mg/kg body weight) was administered for fluorochrome labeling 7 and 2 days prior to euthanasia. Undemineralized distal left tibiae were serial dehydrated and embedded in methylmethacrylate (Sigma-Aldrich M5, 590-9, St. Louis, MO). Serial cross sections (150 to 200 µm) of cortical bone were sectioned (Isomet diamond wafer low-speed saw: Buehler, Lake Bluff, IL) proximal to the tibiofibular junction (TFJ), rinsed of dust debris and mounted on glass slides. The histomorphometric analyses were performed by using the OsteoMeasure Analysis System, Version 1.3 (OsteoMetrics, Atlanta, GA). Measures of labeled surfaces and interlabel widths were obtained at 200x magnification of two sections per animal. If double label did not appear on the first two sections an additional two sections we obtained to search for double label. After an exhaustive search and no double label observed a value of 0.3 um/day was used as the estimated physiological lower limit of MAR (22,66). Periosteal and endocortical mineral apposition rates (MAR, µm/d) were calculated by dividing the average interlabel width by the time
between labels (5 days), and mineralizing surface (MS) for both periosteal and endocortical bone surfaces (BS) using the formula \( \%MS/BS = \{(\text{single-labeled surface}/2) + \text{double-labeled surface}\}/\text{surface perimeter} \) \times 100. Bone formation rate (BFR) was calculated as (MAR x MS/BS).

**Sclerostin Immunohistochemistry**

The distal half of left femora were fixed in 4% phosphate-buffered formalin for 48 hours at 4°C, then decalcified in a sodium citrate-formic acid solution for 14 days, and stored in 70% EtOH. Five millimeter midshaft femoral cross sections were cut and placed in cassettes for paraffin embedding. Following decalcification, they were embedded in paraffin and transverse cortical sections at the midshaft were cut 8 μm thick and mounted on slides. Tissues were processed for sclerostin IHC as described previously (50). Tissues were then placed on a wet-incubation tray and each sample was loaded with the sclerostin primary antibody (1:500 dilution, R&D Systems, Minneapolis, MN) and incubated at 4°C overnight. The quantification of total (N.Ot) and sclerostin-positive osteocytes (SOST+ Ot) was performed over the entire cortical bone cross-section using the OsteoMeasure Analysis System, Version 1.3 (OsteoMetrics, Atlanta, GA). The percentage of sclerostin-positive osteocytes was calculated as \( (\text{SOST+ Ot}/\text{Total Ot}) \times 100 \).

**Serum TRAP 5b**

To quantify systemic osteoclast number, serum concentrations of TRAP 5b were measured. TRAP5b levels were determined by with a TRAP 5b ELISA kit (IDS, Fountain Hills, AZ) according to the manufacturer's instructions. Assay results were
analyzed using a DTX 880 microplate reader (Beckman Coulter; Brea, CA). The intra-
and inter-assay coefficients of variation were < ± 6.5% and 8%, respectively for this
ELISA kit.

*Lipid Peroxidation*

Tibias were snap-frozen and stored at -80°C. Whole tibias were pulverized into a
fine powder with a mortar and pestle, kept cold with liquid nitrogen. The pulverized
bone sample was resuspended in 20 mM of ice-cold PBS. The manufacturer’s standard
ELISA recommended protocol was followed for the quantification of the decomposed
lipid peroxidation products malondialdehyde (MDA) and 4-hydroxyalkenals (HAE)

*Mechanical Testing*

Femoral necks for mechanical testing were brought to room temperature and
wrapped in PBS soaked gauze before testing to failure on an Instron 3345 as previously
described (82). [Note: These mechanical tests were performed in a colleague’s
laboratory (HA Hogan, Mechanical Engineering, Texas A&M University). BR Macias
was assisted by students in Dr. Hogan’s laboratory to perform these mechanical tests. In
addition, data reduction, statistical analysis, and interpretation of the results were
performed by BR Macias.] In short, the proximal half of the femur was placed upright
in a custom metal plate support. A quasi-static load was applied in displacement control
at 1.27 mm/min. The applied load was measured with a 100 Newton (N) load cell. All
data collected during tests were digitized and analyzed by Bluehill software (version
**Statistical Analysis**

All data are presented as mean ± standard deviation (SD) and evaluated using the statistical package SPSS (v.15; Chicago, III). Body mass data are presented as mean ± standard error (SE) for graphical clarity. Data were analyzed using a 2-way ANOVA to test the main effects of partial weightbearing and radiation, with interactions. A fisher's least significant difference post hoc analyses were performed for pairwise comparisons. For all data, statistical significance was accepted at p<0.05.

**Results**

Body weight is reduced during partial weightbearing as compared to cage controls but added radiation exposure does not cause further losses (Figure 5 and 6).

![Figure 5. Effects of G/6 weightbearing and X-ray radiation exposure on body mass. Data are presented as mean ± standard error (SE) for graphical clarity. *The 1G group is significantly different on day 21 from G/6, P<0.05.](image-url)
Figure 6. Effects of G/6 weightbearing and 28Si radiation exposure on body mass. Data are presented as mean ± standard error (SE) for graphical clarity. *The 1G group is significantly different on day 21 from G/6, P<0.05.

Partial Weightbearing and Radiation Exposure Result in Cancellous Bone Loss

Partial weightbearing (G/6) for 21-days results in lower percent BV/TV at the distal femur compared to the full weightbearing cage controls (1G) (Figure 7A and 7D). Fractionating the 1.0 Gy X-ray dose mitigated decrements in cancellous microarchitecture both at 1G and G/6 (Figure 7A-C). Surprisingly however, fractionating 28Si did not show the same protective effect as fractionated X-rays (Figure 7D-F). During full weightbearing, three fractions of 0.17 Gy 28Si produced a 18% lower BV/TV and one acute 0.5 Gy 28Si dose produced a 14% lower BV/TV, compared to SHAM exposed (Figure 7D).
Figure 7. Cancellous microarchitecture during partial weightbearing and X-ray or $^{28}$Si exposure. X-ray: A) BV/TV, Bone Volume B) Tb.N, Trabecular Number C) Tb.Th, Trabecular Thickness. Cancellous microarchitecture during partial weightbearing and $^{28}$Si exposure: D) BV/TV, Bone Volume. E) Tb.N, Trabecular Number F) Tb.Th, Trabecular Thickness. *significant main effect for load condition (1G versus G/6, p<0.05). Those radiation groups within the respective 1G or G/6 load condition not sharing the same letter are significantly different, p<0.05.
Similarly, during partial weightbearing, three fractions of 0.17 Gy $^{28}$Si produced a 12.3% lower percent BV/TV and one acute 0.5 Gy $^{28}$Si dose showed a 8.8% lower BV/TV compared to SHAM exposed (Figure 7D). The highest X-ray dose, 1 Gy, when combined with partial weightbearing, resulted in 33% lower Tb.N compared to full weightbearing SHAM controls (Figure 7B). The magnitude of loss in percent BV/TV was greater when X-ray exposure was combined with partial weightbearing. In addition, fractionating an X-ray dose during partial weightbearing reduced BV/TV by 4% compared to partial weightbearing SHAM exposed animals, not observed in the full weightbearing groups, suggesting that fractionating low LET during partial weightbearing may show a small but different effect compared to that observed during full weightbearing. Partial weightbearing reduced Tb.Th by ~12-13% in both the $^{28}$Si or X-ray experiments. X-ray and $^{28}$Si exposure during full- or partial-weightbearing conditions did not impact Tb.Th.

Partial Weightbearing and Radiation Exposure Impact Cortical Bone Geometry

X-ray exposure did not cause significant decrements in Ct.Ar, J, or Ct.Th (Figure 8A-C). Partial weightbearing suppressed the cortical bone growth at the mid shaft femur (Figure 8D). The fractionated $^{28}$Si radiation dose resulted in a lower Ct.Ar. compared to a full single radiation dose during full weightbearing (Figure 8D). Similarly, polar CMSI (J), was lower with G/6 compared to full weightbearing (Figure 8E). When $^{28}$Si radiation exposure was combined with partial weightbearing, the decrements in Ct.Ar and J are similar to the G/6 SHAM group but lower than the 1G groups.
Figure 8. Partial Weightbearing, X-ray radiation, and $^{28}$Si radiation effects on midshaft femoral cortical geometry. X-ray radiation: A) Cortical bone area, Ct.Ar. B) Polar moment of inertia, J C) Cortical thickness, Ct.Th; $^{28}$Si radiation: A) Cortical bone area, Ct.Ar. B) Polar moment of inertia, J C) Cortical thickness, Ct.Th. *significant main effect for load condition (1G versus G/6, p<0.05).
Partial Weightbearing and Radiation Exposure Reduce Femoral Neck Strength

All groups exposed to partial weightbearing show lower femoral neck strength (Figure 9A and 9D). Partial weightbearing combined with a fractionated 0.5 Gy dose of $^{28}$Si exacerbates disuse-related reductions in femoral neck strength compared to 1G SHAM or the 1G fractionated dose ($p=0.003$). Partial weightbearing, radiation, or the combination of those factors did not significantly lower femoral neck stiffness (Figure 9B and 9E).

Figure 9. Partial Weightbearing and radiation effects on femoral neck mechanical properties. A) Partial weightbearing and $^{28}$Si radiation exposure lower load to failure of the femoral neck. B) Partial weightbearing and X-ray radiation exposure lower load to failure of the femoral neck. C) Partial weightbearing and $^{28}$Si radiation effects on femoral neck stiffness. D) Partial weightbearing and X-ray radiation effects on femoral neck stiffness. *significant main effect for load condition (1G versus G/6, $p<0.05$). † Significantly different from 1G 3F x 0.17 Gy group ($p=0.003$).
Partial Weightbearing Elevates Marker of Osteoclast Number

Partial weightbearing elevates serum TRAP5b levels, a marker of osteoclast number (Figure 10). There was no independent effect of $^{28}$Si radiation.

Figure 10. Partial Weightbearing for 21-days and $^{28}$Si radiation exposure elevates serum TRAP 5b levels compared to 1G cage controls animals. The values are given as mean ± SD. *significant main effect for load condition (1G versus G/6, $p<0.05$).
Partial Weightbearing Combined with $^{28}\text{Si}$ Radiation Exposure Exacerbates the Proportion of Cortical Sclerostin-Positive Osteocytes

The proportion of sclerostin positive osteocytes in cortical bone was higher during G/6 then 1G (Figure 11A and 11B). Unexpectedly, added $^{28}\text{Si}$ radiation exposure during partial weightbearing significantly raised the proportion of sclerostin-positive osteocytes at the mid shaft femur (Figure 11A). X-ray radiation exposure combined with partial weightbearing does not appear to cause the same effect (Figure 11B). However

Figure 11. Proportion of sclerostin positive osteocytes during partial weightbearing and radiation exposure. A) Partial weightbearing and $^{28}\text{Si}$ radiation exposure demonstrates a higher proportion of sclerostin positive osteocytes. B) Partial weightbearing groups demonstrate a higher proportion of sclerostin positive osteocytes. *significant main effect for load condition (1G versus G/6, p<0.05). Within the G/6 load condition those groups not sharing the same letter are significantly different, p<0.05.
due to limited availability of tissue samples in the combined X-ray and partial weightbearing groups (n=6) we can not conclude if low-dose low LET causes the same elevation of cortical sclerostin positive osteocytes as observed in the $^{28}$Si radiation experiment. Nevertheless, in the X-ray experiment we find significantly higher proportion of sclerostin positive osteocytes compared to the full weightbearing controls.

Figure 12. Partial Weightbearing and $^{28}$Si radiation effects on tibial cortical dynamic histomorphometry Effects of reduced gravitational loading on periosteal and endocortical bone surface dynamic histomorphometric analyses measured at the tibia mid-diaphysis. A: Periosteal mineralizing surface (MS/BS). B: Periosteal bone formation rate (BFR). C: Endocortical mineralizing surface (MS/BS). D: Endocortical bone formation rate (BFR). The values are given as mean ± SD. *significant main effect for load condition (1G versus G/6, p<0.05). Those radiation groups within the respective 1G or G/6 load condition not sharing the same letter are significantly different, p<0.05.
**Weightbearing at Less Than 1G Suppresses Bone Formation**

Partial weightbearing potently suppresses mineralization on both periosteal and endosteal surfaces (Figures 12 and 13). Interestingly, a fractionated $^{28}$Si exposure during full weightbearing conditions showed further reductions in MS/BS as compared to SHAM exposed mice (Figure 12C). The fractionated dose group shows a similar suppression of bone formation as compared to the single full dose during partial weightbearing.

---

Figure 13. Partial Weightbearing and X-ray radiation effects on tibial cortical dynamic histomorphometry. Effects of reduced gravitational loading on periosteal and endocortical bone surface dynamic histomorphometric analyses measured at the tibia mid-diaphysis. A: Periosteal mineralizing surface (MS/BS). B: Periosteal bone formation rate (BFR). C: Endocortical mineralizing surface (MS/BS). D: Endocortical bone formation rate (BFR). *significant main effect for load condition (1G versus G/6, p<0.05). Those radiation groups within the respective 1G or G/6 load condition not sharing the same letter are significantly different, p<0.05.
Lipid Peroxidation

A single 0.5 Gy dose of $^{28}$Si during full weightbearing caused a significant doubling of MDA+4HNE in whole tibia homogenates compared to 0 Gy SHAM exposed (Figure 14).

![Lipid Peroxidation](image)

Figure 14. The highest acute $^{28}$Si radiation dose during 1G raises lipid peroxidation levels in tibias after 21-days. *unpaired t-test, significantly different from SHAM exposed, p=0.031.

Discussion

In support of our hypothesis, low-dose high LET radiation exposure exacerbates cancellous bone loss (BV/TV) seen with partial weightbearing. Fractionating low-dose high LET radiation ($^{28}$Si) does not prevent cancellous bone loss. However, fractionating low-dose low LET radiation (X-rays) does protect against cancellous bone loss during...
full weightbearing conditions. Thus, the present data suggest that the effect of fractionation is dependent on LET for cancellous bone tissue.

Dividing a large gamma or proton radiation dose into small fractions is a common therapeutic strategy to deliver a sufficient radiation dose, for example 5-10 Gy to pathological tissue but spare neighboring healthy normal tissue (102). Therefore, utilizing fractionated doses regimes similar to those used in the present study may better simulate the low-dose rate exposures observed in space.

As expected, midshaft cortical areas of the partial weightbearing groups were smaller than in weightbearing cage controls. At the lower 0.5 Gy $^{28}$Si dose tested in the present study there were not significant negative effects on femoral neck mechanical properties. Exposure to radiation doses 2-Gy and above may potently suppress cortical bone growth, potentially masking differences between low- and high LET effects. In addition, these studies further highlight the temporal and tissue dependent effects of radiation exposure.

Three low-dose high LET radiation exposures cause similar cancellous bone loss as compared to a single dose. At higher radiation doses cancellous bone loss after 110-days of 2 Gy high LET ($^{56}$Fe) radiation or low-LET (gamma) radiation were similar (28). Similar to our findings, doses as low as 0.5 Gy $^{56}$Fe radiation demonstrate significant impacts on cancellous bone loss (100).

X-ray radiation impairs osteoblast proliferation and enhances osteoclast maturation (46). The present data show more circulating osteoclasts as evidenced by the higher serum TRAP5b levels in G/6 groups with or without radiation. Radiation induced
elevation of TRA5b is up by 50% as early as 1-day following 2-Gy X-ray radiation, and TRAP5b has been shown to remain elevated 3-days following irradiation by 14% (96). Moreover, higher lipid peroxidation of whole tibia homogenates 21-days after radiation exposure suggests persistent radiation induced oxidative damage in bone tissue. It has been reported previously that oxidative stress can lead to higher bone resorption (37). Limited numbers of snap frozen tissues limited lipid peroxidation measurement to sham and 50 cGy $^{28}$Si full weightbearing groups. The present data suggest that lipid peroxidation of bone tissue may play a role in radiation induced bone loss.

Both partial weightbearing and radiation exposure impair bone formation rate, primarily as a result of a lower MS/BS. This lower MS/BS may indicate impairment of pre-osteoblast proliferation capacity or fewer osteoblasts directed to bone surfaces. We find a lower cortical bone formation rate with partial weightbearing exposure than with radiation exposure during full weightbearing. This disuse-associated suppression of cortical bone formation is consistent with previous investigations (37).

Radiation, especially high-LET radiation, generates a substantial amount of reactive oxygen species, namely hydroxyl radicals (27). Reports suggest that Wnt signaling is antagonized by oxidative stress (52). Nitric oxide is one key molecule implicated in signal transduction of mechanical signals in bone tissue to osteoblasts and osteocytes (14). Thus, elevated levels of reactive oxygen species beyond endogenous cellular antioxidants capacity could quench this mechanically induced nitric oxide signal. This reduction in nitric oxide levels could result in lower than normal mechanical loading signals to osteoblasts and osteocytes leading to an increase in
sclerostin production. Alternatively, radiation-induced suppression of osteoblast proliferation may indirectly result in higher sclerostin-positive osteocytes. Recent data suggest that the mechanical loading-mediated downregulation of sclerostin expression in osteocytes is located near regions of new bone formation (59). Therefore, radiation-induced suppression of osteoblastogenesis could lower the number of mature osteoblasts on bone surface and prevent local signal processing between osteocytes nearby bone cells, resulting in more sclerostin-positive osteocytes.

BALB/cBYJ are highly responsive to the mechanical load environment (33). Thus, use of the BALB/c mice strain may have limited our ability to detect small enhancement of bone loss due to radiation effects when combined with reduced weightbearing. However, utilization of BALB mice for these series of experiment enables direct comparisons with previous data from partial weightbearing literature (46,94).

Data on bone quality during or after Lunar missions do not exist. Moreover, no data exist testing the skeletal consequences of combining low-dose high-LET radiation and partial weightbearing. NCRP’s report 98 highlights the need for more data on the effects of low-dose high-LET radiation.

In support of our hypothesis, low-dose high LET radiation exposure during partial weightbearing conditions exacerbates cancellous bone loss (BV/TV). In addition, fractionating our higher $^{28}$Si dose does not prevent cancellous bone loss. Radiation-induced oxidative stress may explain some of the resultant cancellous bone loss. The number of sclerostin positive osteocytes is higher when exposed to partial weightbearing
and added low-dose high LET radiation compared to SHAM controls. It remains to be determined if bone mass can recover following low-dose high LET exposure. Exercise regimens that reproduce high impact force profiles observed during full weightbearing are an essential component of the bone loss mitigation strategy for both crew members and clinical population.
CHAPTER IV

COMBINED SIMULATED RESISTANCE TRAINING AND GSK3 INHIBITION INCREASES BONE MASS DURING DISUSE

Introduction

Approximately 1.5 million osteoporotic-related fractures occur annually in the United States (9) and these fractures are one of the most common causes of disability (20). As a result, the direct care expenditures for osteoporotic fractures are estimated to be as high as $17.9 billion (86).

Weight bearing exercise early in life contributes to high peak bone mass; however, bone loss ensues if the exercise program terminates (34). Mechanical loading of bone, as during high impact exercise activities, induces site-specific changes in bone architecture and increased bone mass (30,43). Moreover, regular physical activity improves mobility and muscle function; it may also indirectly reduce the risk of falls thereby reducing fracture incidence. In fact, exercise during extreme periods of disuse in humans such as bed rest maintains aerobic capacity (44), promotes bone formation (80), and maintains lumbar spine structure and function (49).

Reduced weightbearing conditions during spaceflight result in 1-2% bone loss per month of preflight baseline values at the femoral neck and lumbar spine (40). The rodent hindlimb unloading (HU) model is a well-established ground-based model for investigating disuse effects on bone (58). Recently, high intensity muscle contractions at 75-to-100% peak isometric torque (P_0), produced during simulated resistance training
(SRT) undertaken during a period of HU show significant gains in mid-diaphyseal tibia cortical bone mineral density (BMD) (50, 83). These gains were associated with a 2.6- to 5-fold greater periosteal bone formation rate as compared to control animals (50, 83). Therefore, high intensity exercise provides some protection against disuse-induced bone loss in rodent ground based simulations of microgravity.

Data over the last ten years strongly suggests that the Wnt pathway is a major regulator of bone formation; however, the basic molecular mechanisms governing the osteogenic response to mechanical load are unknown. Loss-of-function mutation of the low-density lipoprotein receptor-related protein 5 (Lrp5) gene impairs the response to mechanical load and decreases osteoblast proliferation and bone mass (24). Mechanical loading promotes formation of the Wnt-LRP4/5/6-Frizzled transmembrane complex. Formation of the receptor complex permits disheveled (Dsh) to inhibit the cytoplasmic formation of GSK-3β, APC and Axin-2 and allowing intracellular β-catenin levels to rise. Once β-catenin levels are sufficiently high, β-catenin translocates to the nucleus where it associates with T-cell factor (TCF)/lymphoid enhancer-binding factor (LEF) transcription factors to activate the osteogenic gene expression program (18). Moreover, the Wnt pathway functions to coordinate communication between mechanosensing osteocytes (via secreted sclerostin) and bone-forming osteoblasts by the binding of sclerostin to other Lrp receptors, for example Lrp4 and Lrp6 (16, 47, 98).

GSK-3β is a key modulator of the Wnt signaling pathway and has been a target of drug development to resolve metabolic and neurological diseases. Inhibition of GSK-3β can normalize blood glucose levels in an animal model (17) and suppress neuronal
apoptosis (6). Given the efficacy of GSK-3β inhibitors to affect downstream Wnt signaling, they have recently been used to experimentally activate Wnt signaling in bone cells and increase bone mass in rodent models (38,54). GSK-3β inhibition prevents ovariectomized-induced femoral bone loss in rodents (38). In another report, femoral cancellous and cortical BMD were higher when treated with a GSK-3β inhibitor as compared to vehicle-treated controls (54). However, it is unclear whether inhibition of GSK-3β can mitigate bone loss during disuse or how GSK-3β inhibition interacts with increased mechanical loading.

Current exercise hardware and exercise prescriptions performed during ISS missions (~6 months) does not completely prevent musculoskeletal deconditioning but may mitigate some of the musculoskeletal loss (73,76,78,81,87). Recent data show that when exercise on the advanced resistive exercise device (aRED) is combined with adequate nutrition astronauts show no net bone loss after 6 month ISS missions at most bone sites (76). These human exercise evaluations during microgravity provide further evidence that high impact resistive exercise prescriptions are necessary to prevent bone loss during long duration space missions.

Pharmaceuticals targeting the Wnt signaling pathway are currently being developed to treat osteoporosis and aid fracture healing (NCT01144377). It is unclear how pharmaceutical perturbations of Wnt signaling during disuse or with exercise affect bone loss. Therefore, the purpose of this study was to investigate the interaction of GSK-3 inhibition and resistance exercise imposed during simulated microgravity. We hypothesized that simulated resistance training combined with a GSK-3 inhibitor
treatment during hindlimb unloading would most effectively mitigate disuse-induced
decrements in cancellous and cortical bone geometry.

**Materials and Methods**

**Animals and Experimental Design**

Forty male, Sprague-Dawley rats (6-mo-old) were obtained from Harlan
(Houston, TX) at 6 months of age and allowed to acclimate for 14 days prior to initiation
of the study. All animals were singly housed after arriving at our animal facility in a
temperature-controlled (23 ± 2°C) room with a 12-hour light-dark cycle in an American
Association for Accreditation of Laboratory Animal Care-accredited animal care facility
and were provided standard rodent chow (Harlan Teklad 8604) and water ad-libitum.
Animal care and all experimental procedures described in this investigation were
approved by the Texas A&M University Laboratory Animal Care Committee.

Six experimental groups were studied: (1) cage control (CC+Vh, n=10), (2) CC
animals administered a GSK-3 inhibitor 0.2mg/kg (2'Z,3'E)-6-Bromoindirubin-3'-oxime
(BIO) via subcutaneous injection once per week (CC+BIO, n=10), (3) hindlimb
unloaded (HU+Vh, n=10), (4) HU animals administered 0.2mg/kg BIO via subcutaneous
injection 1 time/week (HU+BIO, n=10), (5) HU subjected to simulated resistance
training (HU+SRT/Vh, n=10), and (6) HU rats subjected to both BIO and SRT
(HU+SRT/BIO, n=10). All animals completed the 28-day protocol and maintained
normal activity and appeared healthy. Animals in all groups except CC underwent 28
days of HU. HU+SRT and HU+SRT/BIO animals underwent 9 sessions of simulated
resistive exercise conducted once every three days during the 28 day protocol. The CC animals were allowed normal ambulatory cage activity.

Calcein injections (25 mg/kg body mass) were given subcutaneously 9 and 2 days prior to euthanasia to label mineralizing bone for histomorphometric analysis. HU animals were anesthetized before removal from tail suspension at the end of the study to prevent any weight bearing by the hindlimbs. At the end of the experiment, on day 28, all animals were anesthetized with 50 mg/kg BW of ketamine (Fort Dodge Animal Health; Fort Dodge, IA) and 0.5 mg/kg BW of medetomidine (Pfizer; New York, NY) and euthanized by decapitation. Approximately 5 to 6 ml of blood was collected by cardiac puncture and allowed to clot for 20 minutes before centrifugation. Serum was collected and stored at -80°C until analysis. Proximal left tibiae were fixed in formalin, then stored in 70% ethanol at 4°C for histomorphometry analyses; proximal femurs were thoroughly cleaned of soft tissue, wrapped in gauze soaked with phosphate-buffered saline (PBS), and stored at -20°C for ex vivo pQCT scanning and mechanical testing.

**Hindlimb Unloading**

Hindlimb unloading was achieved by tail suspension as previously described (82). The height of the animal’s hindquarters was adjusted to prevent any contact of the hindlimbs with the cage floor, resulting in approximately a 30° head-down tilt. The forelimbs of the animal maintained contact with the cage bottom, allowing the rat full access to the entire cage. All animals were monitored daily for health, including assessment of tail integrity, and body weights were measured weekly.
Simulated Resistance Training (SRT) Paradigm

Simulated resistance training was completed as previously described (100). Briefly, left plantarflexor muscles from animals in the HU+SRT/Vh and HU+SRT/BIO groups were trained once every 3 days during 28-day HU using a custom-made rodent isokinetic dynamometer. Animals were anesthetized with isoflurane gas (~2.5%; Minrad Inc., Bethlehem, PA) mixed with oxygen before removal from tail suspension to prevent any weight bearing by the hind limbs. Each rat was then placed in right lateral recumbency on a platform, the left foot was secured onto the foot pedal, and the left knee was clamped so that the lower leg was perpendicular to the foot and the femur and tibia were at right angles to each other. This was referred to as the resting, 0° position. For isometric contractions, the foot pedal was held fixed in this position; to generate eccentric contractions of the plantarflexor muscles, the foot pedal moved the foot into 40° of dorsiflexion. For all contractions, the footplate was rotated in synchrony with muscle stimulation by a Cambridge Technology lever system (Model 6900) interfaced with a 80486 66-MHz PC using custom software written in TestPoint (v.4.0; Capital Equipment Corp., Billerica, MA). Torque generated around the footplate pivot (at the rat’s ankle joint) was measured by the lever system’s servomotor. Plantarflexor muscle stimulation was performed with fine wire electrodes consisting of insulated chromium nickel wire (Stablohm 800B, H-ML Size 003, California Fine Wire Co.), inserted intramuscularly straddling the sciatic nerve in the proximal thigh region. The stimulation wires were then attached to the output poles of a Grass Instruments stimulus isolation unit (Model SIU5; Astro-Med, Inc; W. Warwick, RI) interfaced with a
stimulator (S88; Astro-Med, Inc; W. Warwick, RI) which delivered current to the sciatic nerve and induced muscle contraction.

Voltage optimization to achieve peak isometric torque and stimulation frequency optimization of the eccentric torque were performed at the beginning of each session, as described previously (83). The eccentric phase of the muscle contraction was titrated to equal ~75% of each animal’s daily peak isometric torque (P_o). The HU+SRT/Vh and HU+SRT/BIO animals completed a combined isometric+eccentric simulated resistance training (SRT) exercise paradigm, consisting of 4 sets of 5 repetitions, once every 3 days during HU (n=9 total exercise sessions). The training paradigm consisted of a 1000 ms isometric contraction (75% P_o), immediately followed by a 1000 ms eccentric contraction (75% P_o).

(2'Z,3'E)-6-Bromoindirubin-3'-oxime Treatment

Animals in the CC+BIO, HU+BIO, and HU+SRT/BIO groups were administered 0.2mg/kg (2'Z,3'E)-6-Bromoindirubin-3'-oxime (BIO) (R&D Systems, Inc.; Minneapolis, MN) via subcutaneous injection once per week for the duration of the 28-day study. BIO is a potent and selective glycogen synthase kinase-3 (GSK-3) inhibitor (55). The BIO dose of 0.2mg/kg/week was previously shown to attenuate reductions in cancellous bone loss (%BV/TV) at the proximal tibia of rats during six weeks of methylprednisolone treatment (95). Rats in the CC+Vh, HU+Vh, and HU+SRT/Vh groups were administered an equal concentration and volume of vehicle (dimethyl sulfoxide) by subcutaneous injection each week.
Peripheral Quantitative Computed Tomography (pQCT)

On days -1 and 28 of the study, pQCT scans were performed in vivo at the proximal tibia metaphysis (PTM) and tibia mid-diaphysis with a Stratec XCT Research-M device (Norland Corp., Fort Atkinson, WI), using a voxel size of 100 μm and a scanning beam thickness of 500 μm. Two slices centered at 50% of the tibial total length (determined from a scout view on the CT scanner) were collected. Calibration of this machine was performed on each day of scanning with a hydroxyapatite standard cone phantom. A standardized analysis for diaphyseal bone (contour mode 1, peel mode 2, outer threshold of 0.650 g/cm³, inner threshold of 0 g/cm³) was applied to each section.

Values of cortical bone mineral content (BMC), cortical bone area, and the polar cross-sectional moment of inertia (CSMI) were averaged across the 2 slices at the tibial mid-diaphysis to yield a mean value. Polar CSMI was based on geometry only and not weighted by density. Machine precision for cortical vBMD (based on manufacturer’s data) is ±9 mg/cm³ for cortical bone. Reproducibility in our laboratory was determined from five repeat scans using a in vivo multiple-slice scanning method; resulting coefficients of variation for cortical tibia BMD was ±0.59%.

Values of total volumetric bone mineral density (vBMD), total bone mineral content (BMC), total bone area, and cancellous vBMD were averaged across the 3 slices at the proximal tibia to yield a mean value. Machine precision (based on manufacturer’s data) is ±3 mg/cm³ for cancellous vBMD. Coefficients of variation were ±0.6, 1.6, 1.9,
and 2.13% for \textit{in vivo} proximal tibia total vBMD, total BMC, total area, and cancellous vBMD respectively, as determined from repeat scans on each of 6 adult male rats.

\textit{Ex Vivo pQCT}

Following euthanasia, excised femurs were scanned \textit{ex vivo} at the femoral neck (FN) using a voxel size of 70 \(\mu\)m to characterize mineral properties and cross-sectional geometry. The proximal half of the femur was placed in a mold designed to hold the femoral neck in alignment with the scanning axis of the CT scanner (8,32). A scout view scan was performed, and three adjacent scan slices (500 \(\mu\)m) were made of the femoral neck starting just below the femoral head, with values averaged for 2 or 3 slices.

\textit{Dynamic Histomorphometry Analysis}

Undemineralized distal left tibiae were subjected to serial dehydration and embedded in methylmethacrylate (Sigma-Aldrich M5, 590-9, St. Louis, MO). Serial cross sections (150 to 200 um) of midshaft cortical bone were cut starting 2.5mm proximal to the tibiofibular junction (TFJ) with an Isomet diamond wafer low-speed saw (Buehler, Lake Bluff, IL). The histomorphometric analyses were performed by using the OsteoMeasure Analysis System, Version 1.3 (OsteoMetrics, Atlanta, GA). Measures of labeled surfaces and interlabel widths were obtained at 200x magnification of up to two slides per animal. Periosteal and endocortical mineral apposition rates (MAR, \(\text{um/d}\)) were calculated by dividing the average interlabel width by the time between labels (7 days), and mineralizing surface (MS) for both periosteal and endocortical bone surfaces (BS) using the formula \(\%\text{MS/BS} = \{[(\text{single-labeled surface}/2) + \text{double-labeled}\ldots] \right) \text{um/d} \)
Bone formation rate (BFR) was calculated as (MAR x MS/BS).

Micro-computed Tomography (µCT)

Microcomputed tomography (µCT SkyScan 1172; SkyScan, Kontich, Belgium) was used to quantify 2D and 3D microarchitecture. [Note: These uCT scans and reconstructions were performed in a colleague’s laboratory (MR Allen, Indiana University School of Medicine, Indianapolis). Data reduction, statistical analysis, and interpretation of the results were performed by BR Macias.] The ex-vivo right and left proximal tibia were scanned using an X-ray source set at 60kV over an angular range of 180 degrees with rotational steps of 0.70 degrees. Projection images were attained at 6-µm resolution and then reconstructed and analyzed using manufacturer-provided software (NRecon and CTAn; SkyScan). For trabecular bone analyses, a 1 mm long segment of the distal metaphysis secondary spongiosa was defined and the trabecular region within the segment was manually traced. A threshold was applied to separate bone from soft tissue (range, 100 to 255), and then the specimen was analyzed in 3 dimensions for bone volume/ trabecular volume (BV/TV), trabecular number (Tb.N), and trabecular thickness (Tb.Th). All nomenclature follows currently accepted guidelines for micro-computed tomographic evaluation of bone (13).

Femoral Neck Mechanical Testing

Specimens were brought to room temperature and all tests were performed on hydrated specimens using a material testing machine (Instron 3345, Norwood, MA) with a 1000-N load cell. [Note: These mechanical tests were performed in a colleague’s
laboratory (HA Hogan, Mechanical Engineering, Texas A&M University). BR Macias was assisted by students in Dr. Hogan’s laboratory to perform these mechanical tests. In addition, data reduction, statistical analysis, and interpretation of the results were performed by BR Macias.] Load and displacement data were collected at 10Hz during tests and analyzed using Bluehill software (version 2.14.582, Instron Bluehill) and a custom-written Matlab (version 7.12.0, The MathWorks, Inc.) program. Mechanical properties of the femoral neck were evaluated using an axial loading configuration.

Each proximal femur was placed upright with the diaphysis portion of the bone firmly inserted into a properly sized and fitted hole in a ½-inch thick aluminum plate fixture. A 10-mm cylindrical platen with a flat head was used to apply a load to the femoral head, parallel to the axis of the shaft of the femur. Quasi-static loading was applied in displacement control (2.54 mm/min) until fracture occurred. Load-displacement curves were analyzed to determine the structural variables of ultimate force (F) and stiffness (S), the latter of which was defined to be the slope of the elastic linear portion of the loading curve.

*Serum Interleukin 6 (IL-6)*

Serum IL-6 on cardiac blood samples collected at sacrifice was determined using the Rat IL-6 immunoassay Quantikine® ELISA (R&D Systems, Inc.; Minneapolis, MN) according to the manufacturer’s instructions. All samples were run in duplicate and fit onto one plate to run this assay. Assay results were analyzed using a DTX 880 microplate reader (Beckman Coulter, Brea, CA, USA). The interassay coefficient of variation was found to be 8%.
Statistical Analyses

All data were expressed as means ± SD and evaluated using the statistical package SPSS (v.15; Chicago, Ill). Data were first analyzed using a two-factor ANOVA (exercise and drug) to compare group differences between HU groups (HU+Vh, HU+BIO, HU+SRT/Vh, and HU+SRT/BIO). A Tukey’s post-hoc test was used for pair-wise comparisons. Subsequently, a one-factor ANOVA was used to compare HU groups’ values vs. that of the comparator cage control (CC) group (Tukey’s post-hoc test for pairwise comparisons). A one-factor ANOVA was employed to determine significant longitudinal pQCT variable changes within each treatment group (in vivo pQCT data only). An un-paired t-test tested differences between the HU+SRT and HU+SRT/BIO groups to determine the effect of added BIO treatment. For all data, statistical significance was accepted at p<0.05.

Results

Simulated Resistance Exercise Combined with Inhibition of GSK-3 Prevents Disuse Induced Cancellous Volumetric BMD Losses

Cancellous proximal tibia total BMC was significantly lower by 11% after 28-days of HU (p<0.05) (Table 1). BIO treatment halved this HU-induced 11% loss of total BMC at the proximal tibia metaphysis (HU+Vh versus HU+BIO, p=0.03). SRT significantly increased total BMC and total bone area at the proximal tibia metaphysis during HU (p<0.001 and p=0.002, respectively). The gain in total BMC after 28-days was similar between the HU+SRT/Vh and HU+SRT/BIO groups. Similarly, SRT significantly increased total bone area (area inside periosteal edge) at the proximal tibia
metaphysis by ~2% compared to the suppressed growth in the non-exercise control groups (p<0.001). Moreover, BIO treatment combined with SRT enhanced gains in cancellous vBMD after 28-days HU, producing a significant 8.8% increase as compared to the 2.7% (non-significant) increase with SRT alone (HU+SRT/Vh).

### Table 1. Proximal Tibia Morphometry

<table>
<thead>
<tr>
<th></th>
<th>CC+Vh</th>
<th>CC+BIO</th>
<th>HU+Vh</th>
<th>HU+BIO</th>
<th>HU+SRT/Vh</th>
<th>HU+SRT/BIO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total BMC (mg)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 0</td>
<td>10.70 ± 0.50</td>
<td>10.88 ± 0.78</td>
<td>11.21 ± 0.92</td>
<td>10.44 ± 0.86</td>
<td>11.17 ± 0.58</td>
<td>10.82 ± 0.86</td>
</tr>
<tr>
<td>Day 28</td>
<td>11.20 ± 0.47*</td>
<td>11.29 ± 0.62*</td>
<td>9.96 ± 0.51*</td>
<td>9.87 ± 0.86*</td>
<td>11.98 ± 0.54*</td>
<td>11.52 ± 0.94*</td>
</tr>
<tr>
<td>%-Change</td>
<td>4.69%</td>
<td>3.96%</td>
<td>-10.81%</td>
<td>-5.37%</td>
<td>7.39%</td>
<td>6.57%</td>
</tr>
<tr>
<td><strong>Total vBMD (mg/cm³)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 0</td>
<td>608.84 ± 33.64</td>
<td>612.35 ± 29.66</td>
<td>599.64 ± 24.09</td>
<td>614.59 ± 34.94</td>
<td>602.72 ± 21.12</td>
<td></td>
</tr>
<tr>
<td>Day 28</td>
<td>635.93 ± 36.96</td>
<td>624.40 ± 32.59</td>
<td>612.41 ± 30.44</td>
<td>646.33 ± 38.57</td>
<td>629.30 ± 20.34</td>
<td></td>
</tr>
<tr>
<td>%-Change</td>
<td>4.46%</td>
<td>1.96%</td>
<td>-6.36%</td>
<td>-5.06%</td>
<td>5.24%</td>
<td>4.44%</td>
</tr>
<tr>
<td><strong>Total Bone Area (mm²)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 0</td>
<td>17.67 ± 1.63</td>
<td>17.79 ± 1.14</td>
<td>18.39 ± 1.67</td>
<td>17.45 ± 1.67</td>
<td>18.25 ± 1.42</td>
<td>18.00 ± 1.76</td>
</tr>
<tr>
<td>Day 28</td>
<td>17.71 ± 1.53</td>
<td>18.13 ± 0.86</td>
<td>17.47 ± 1.70</td>
<td>17.38 ± 1.73</td>
<td>18.61 ± 1.21</td>
<td>18.33 ± 1.42</td>
</tr>
<tr>
<td>%-Change</td>
<td>0.31%</td>
<td>2.03%</td>
<td>-4.56%</td>
<td>-0.30%</td>
<td>2.19%</td>
<td>2.07%</td>
</tr>
<tr>
<td><strong>Cancellous vBMD (mg/cm³)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Day 0</td>
<td>201.42 ± 32.63</td>
<td>217.98 ± 34.72</td>
<td>215.18 ± 45.92</td>
<td>199.37 ± 25.30</td>
<td>210.05 ± 24.85</td>
<td>201.57 ± 28.21</td>
</tr>
<tr>
<td>Day 28</td>
<td>187.94 ± 34.87</td>
<td>204.16 ± 30.44</td>
<td>198.55 ± 35.05</td>
<td>187.91 ± 28.32</td>
<td>214.32 ± 28.60</td>
<td>218.74 ± 31.29</td>
</tr>
<tr>
<td>%-Change</td>
<td>-6.44%</td>
<td>-5.90%</td>
<td>-6.71%</td>
<td>-5.28%</td>
<td>2.74%</td>
<td>8.80%</td>
</tr>
</tbody>
</table>

BIO treatment attenuates disuse associated decreases in total BMC (p=0.03). *Significantly less than CC+Vh, p=0.014. †Significantly less than CC+BIO, p=0.014. ‡p<0.05 vs. pre value. Those HU groups not sharing the same letter for each variable are significantly different from each other (p<0.05).

The lower cancellous vBMD after 28-days in both cage control groups may suggest some age-related losses; however, the change was non-significant. However, when HU was imposed for 28 days, cancellous vBMD was significantly lower by 6.7%.

**Simulated Resistance Exercise or Combined GSK-3 Inhibitor Administration Improves Cancellous Microarchitecture**

Both SRT treatment alone or SRT treatment combined with weekly BIO treatment caused significant gains in proximal tibia cancellous BV/TV (p<0.05) (Figure 15). However, these ex vivo end-point µCT measures were unable to detect a difference between the HU+SRT/Vh and HU+SRT/BIO groups. Both T.Th and T.N show a similar
Figure 15. Effects of hindlimb unloading (HU) with or without GSK-3 (BIO) treatment and/or simulated resistance training (SRT) on cancellous bone microarchitecture.  
A: Bone Volume (%BV/TV).  
B: Trabecular Thickness (Tb.Th.).  
C: Trabecular Number (Tb.N.).  
Vertical dashed line indicates separation of CC from the experimental groups for preliminary 2-way ANOVA.  Those HU groups not sharing the same letter for each variable are significantly different from each other (p<0.05).  
*Significantly different versus CC (p<0.05).
response to the 3-times weekly SRT or the combined weekly BIO administration. In rats given BIO treatment only during 28-days HU (HU+BIO), similar decrements in BV/TV, T.Th, and Tb.N as seen in the HU+Vh control group are observed. Interestingly, BIO administration to full weightbearing animals show higher BV/TV, T.Th and Th.N compared to the CC+Vh control group (P<0.05).

*Simulated Resistance Exercise Combined with GSK-3 Inhibitor Administration not only Mitigates Suppressed Cortical Growth but also Stimulates Gain during Disuse*

The magnitude of change in cortical BMC of the HU+SRT/BIO was significantly greater than the magnitude of change observed in the other HU groups (Table 2). When SRT and BIO treatments are combined, the magnitude of change for cortical BMC was greater (6.5%) at the midshaft tibia as compared to the ~4% increase observed in the other HU groups, but non-significant (p=0.06). Similarly, the 2.6% increase in cortical area in the HU+SRT/BIO was significantly greater than the 0.7% increase observed in the HU+SRT/Vh group (p<0.05). These gains in cortical midshaft tibia BMC and area likely contributed to the significant increase in cortical thickness observed when SRT was combined with BIO treatment during disuse (p<0.05). These gains in cortical midshaft BMC, area, and thickness resulted in the 7% gain in polar CSMI (p=0.06).
Table 2. Cortical Midshaft Tibia Bone Morphometry

<table>
<thead>
<tr>
<th></th>
<th>CC+Vh</th>
<th>CC+BIO</th>
<th>HU+Vh</th>
<th>HU+BIO</th>
<th>HU+SRT/Vh</th>
<th>HU+SRT/BIO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortical BMC (mg)</td>
<td>Day 0</td>
<td>8.42 ± 0.57</td>
<td>8.54 ± 0.77</td>
<td>8.94 ± 0.76</td>
<td>8.56 ± 0.58</td>
<td>8.98 ± 0.62</td>
</tr>
<tr>
<td></td>
<td>Day 28</td>
<td>8.75 ± 0.74*</td>
<td>8.95 ± 0.67*</td>
<td>9.28 ± 0.74*</td>
<td>8.89 ± 0.62*</td>
<td>9.33 ± 0.79*</td>
</tr>
<tr>
<td>%-Change</td>
<td>3.87%</td>
<td>5.80%</td>
<td>3.83%</td>
<td>3.90%</td>
<td>3.93%</td>
<td>6.48%</td>
</tr>
<tr>
<td>Cortical Area (mm²)</td>
<td>Day 0</td>
<td>8.78 ± 0.91</td>
<td>8.94 ± 0.89</td>
<td>9.03 ± 0.81</td>
<td>8.93 ± 0.73</td>
<td>8.97 ± 0.87</td>
</tr>
<tr>
<td></td>
<td>Day 28</td>
<td>8.84 ± 0.88</td>
<td>9.01 ± 0.67</td>
<td>9.04 ± 0.83</td>
<td>9.09 ± 0.75</td>
<td>9.03 ± 0.79</td>
</tr>
<tr>
<td>%-Change</td>
<td>0.84%</td>
<td>1.09%</td>
<td>0.43%</td>
<td>1.82%</td>
<td>0.73%</td>
<td>2.65%</td>
</tr>
<tr>
<td>Cortical Thickness (mm)</td>
<td>Day 0</td>
<td>0.74 ± 0.03</td>
<td>0.74 ± 0.04</td>
<td>0.77 ± 0.03</td>
<td>0.74 ± 0.03</td>
<td>0.79 ± 0.04</td>
</tr>
<tr>
<td></td>
<td>Day 28</td>
<td>0.76 ± 0.03</td>
<td>0.77 ± 0.04*</td>
<td>0.79 ± 0.03*</td>
<td>0.75 ± 0.04</td>
<td>0.80 ± 0.04</td>
</tr>
<tr>
<td>%-Change</td>
<td>2.14%</td>
<td>4.16%</td>
<td>2.97%</td>
<td>1.26%</td>
<td>1.70%</td>
<td>4.66%</td>
</tr>
<tr>
<td>CSMI (mm⁴)</td>
<td>Day 0</td>
<td>12.00 ± 2.39</td>
<td>12.35 ± 2.26</td>
<td>12.92 ± 2.39</td>
<td>12.43 ± 1.96</td>
<td>12.76 ± 2.55</td>
</tr>
<tr>
<td></td>
<td>Day 28</td>
<td>12.18 ± 2.32</td>
<td>12.54 ± 1.70</td>
<td>13.17 ± 2.52</td>
<td>12.99 ± 2.16#13.05 ± 2.32</td>
<td>12.21 ± 1.83*</td>
</tr>
<tr>
<td>%-Change</td>
<td>2.09%</td>
<td>2.54%</td>
<td>1.22%</td>
<td>4.64%</td>
<td>2.82%</td>
<td>7.12%</td>
</tr>
</tbody>
</table>

Cortical bone mineral content (BMC), cortical area, cortical thinkness, and polar cross-sectional moment of inertia (CSMI). Values are group mean ± standard deviation of the mean. *p<0.05 vs. pre value. †The magnitude of change in the HU+SRT/BIO group is significantly greater than that in the HU+SRT/Vh, p<0.05. ‡The magnitude of change in the HU+SRT/BIO group was greater than the HU+SRT/Vh but non-significant (p=0.055). †The magnitude of change in the HU+SRT/BIO group was greater than the HU+SRT/Vh but non-significant (p=0.06). §The magnitude of change in the HU+BIO group was greater than the HU+Vh but non-significant (p=0.07).

Simulated Resistance Exercise or Combined GSK-3 Inhibitor Administration Increases Bone Formation on Cortical Surfaces

Cortical midshaft tibia MS/BS, MAR, and BFR were suppressed after 28-days HU as compared to the full weightbearing controls (Figure 16). Rats experiencing SRT during HU exhibited a significantly higher MS/BS on both the periosteal and endocortical surfaces (p<0.05). SRT produced significantly higher MAR and BFR on the periosteal surface (p<0.05) and a non-significant increase in MAR and BFR on the endocortical surface. In addition, by day 28 MAR of the SRT groups was not significantly different from levels in full weight bearing cage controls. Periosteal BFR in HU/SRT rats remained lower than in full weight bearing controls; however, when SRT was combined with a GSK-3 inhibitor BFR was not significantly different from full weight bearing controls.
Figure 16. Effects of hindlimb unloading (HU) with or without GSK-3 (BIO) and/or simulated resistance training (SRT) on periosteal and endocortical surface dynamic histomorphometric analyses measured at the tibia diaphysis. A: Mineralizing Surface (%MS/BS). B: Mineral Apposition Rate (MAR). C: Bone Formation Rate (BFR). Vertical dashed line indicates separation of cage control (CC) from the experimental groups for preliminary ANOVA. Those HU groups not sharing the same letter for respective surface measures are significantly different from each other (p<0.05). *Significantly different vs. CC (p<0.05). Error bars not visible above bars have small SD values.
Figure 17. Femoral neck bone mineral content and strength. A: Combined SRT and GSK3 inhibition produced higher total bone mineral content at the femoral neck compared to the non-treated control, HU+Vh group (*unpaired t-test, p=0.08). B: Combined SRT and GSK3 inhibition (HU+SRT/BIO) resulted in higher femoral neck maximal force compared to HU+BIO (paired t-test, p=0.09).

Simulated Resistance Exercise Combined with GSK-3 Inhibitor Administration during Disuse Restores Femoral Neck Bone Mineral Content

SRT during HU produced non-significant increases in total BMC at the femoral neck; the higher value in the HU+SRT/BIO group compared to HU+Vh group produced a p-value equal to 0.08 (Figure 17A). Femoral neck strength was not affected by SRT+BIO (Figure 17B).

Disuse for 28-days Shows Higher Serum IL-6 Levels

Circulating IL-6 as measured in cardiac serum was significantly higher after 28-days of HU as compared to the full weight bearing controls (HU+Vh), p<0.05 (Figure 18). BIO treatment mitigated this increase resulting in serum IL-6 levels not significantly higher than in cage control rats.
Figure 18. Serum IL-6 after 28-days of disuse (HU+Vh) is significantly higher compared to those levels in full weight bearing controls. Those groups not sharing the same letter are significantly different from each other (p<0.05).

Discussion

In support of our hypothesis, simulated resistance training (SRT) combined with pharmacological activation of the Wnt signaling pathway resulted in greater cortical and cancellous bone mass gains than SRT alone during disuse. Higher bone formation rate observed in the SRT legs explains the observed cortical morphological adaptations. These are the first data to test the combination of mechanical loading and pharmacological activation of Wnt signaling during disuse. The present data do not, however, demonstrate a consistent a synergistic effect of combined SRT and GSK-3 inhibition. However, the combined treatment did result in larger gains in several measures of cortical and cancellous bone compared to the SRT control (HU+SRT/Vh). For example, in the HU+SRT/BIO group we observe an increased cancellous vBMD, midshaft tibia cortical BMC, cortical area, cortical thickness, CSMI, and periosteal BFR
compared to HU+SRT/Vh group. Disuse potently stimulates bone resorption and suppresses bone formation. SRT has previously been shown to restore bone formation but may not affect elevated resorption observed during disuse. However, SRT combined with bisphosphonate therapy has been shown to simultaneously increase bone formation and decrease a serum marker of bone resorption (84). Combining mechanical loading and GSK-3 inhibition provides a small additional increment in bone formation capacity; however, net bone mass gains may be limited by the disuse-induced elevation of bone resorption.

Treatment with GSK3 inhibitors significantly increases cortical and cancellous bone mass during full weightbearing status. A orally bio-available GSK-3 inhibitor given once daily (20mg/kg) produces a 172% increase in bone mineral content, with most of this increase in bone mass was localized to the cancellous bone compartment (54). This increase in bone mass was matched by a 5-fold increase in cancellous bone formation rate and a significant but less robust elevation in periosteal osteoblast activity (54). BIO administration (the same drug and dose as used in the present study) attenuated glucocorticoid-induced cancellous bone loss and normalized cancellous bone formation rate (95). GSK-3 inhibition when combined the SRT treatment in our study resulted in greater periosteal expansion, as evidenced by the higher total bone area and total BMC at the proximal and midshaft tibia in the present study. This bone gain may have been a result of the higher BFR on the periosteal surface. Notably, there was a higher endocortical mineralizing surface (%MS/BS) in SRT treated animals than in other HU groups. Although there were not significant gains in endocortical BFR with added
GSK-3B inhibition during exercise, any increase in BFR on this surface is of special physiological significance, since few exercise or drug interventions increase endocortical bone formation rate. Treatment with GSK-3 inhibitors during normal full weight bearing status, without added exercise interventions, does not affect bone formation rate on the endocortical surface (54). Interestingly, the present data show combining simulated resistance exercise with drugs that activate Wnt signaling may stimulate additional increments in both periosteal and endocortical bone formation rate compared to high intensity exercise modalities alone.

GSK-3 is a key intracellular protein within the putative mechanosensing Wnt pathway. Pharmacological inhibition of GSK-3 combined with SRT may allow sufficient accumulation of β-catenin levels and activate gene expression patterns to increase osteoblastogenesis and osteoblast activity. The mechanical loading to bone tissue provided by SRT likely induced progenitors to differentiate towards the osteoblast cell fate (84). In previously published work, Swift and co-workers demonstrated that SRT causes a shift in marrow cell populations away from adipocytes and towards a greater number of osteoblasts (84). Inhibiting GSK-3 may have amplified this committed subpopulation of progenitors with osteogenic potential, as GSK-3β inhibitor cell culture studies suggest (23). The fluorochrome label data in the present study suggest that SRT significantly increased the number of osteoblasts on cortical bone surface (%MS/BS). While HU+SRT/BIO limb bone did not exhibit significantly higher MAR and BFR compared to the HU+SRT group, the mean value was higher. Using a higher BIO dose or more potent drug may produce significant effects of combined
pharmacological and exercise therapies to better restore osteoblast activity during disuse on the endocortical surface.

It is clear that NASA management is open to exploring pharmacological management of flight-induced bone loss. However, employing a pharmacological approach is challenging in the context of long duration spaceflight. For example, pharmacokinetics can be altered during spaceflight and use of pharmaceuticals approved for treatment of disease, may be problematic for use in normal healthy astronauts. In addition, NASA must choose only the most critical pharmaceutical therapies in order to minimize spacecraft mass and volume. Alendronate is a type of bisphosphonate that potently suppress accelerated osteoclast-mediated bone resorption. Currently, alendronate, an anti-resorptive bisphosphonate, is being administered to some astronauts aboard the ISS to investigate the efficacy of this bone loss countermeasure strategy (41).

Elevated IL-6 levels are associated with increased bone resorption. Bone cells isolated from animals exposed to disuse showed a significantly higher production of IL-6 compared to full weight bearing control samples (25). The present finding of higher serum IL-6 after 28 days of HU is consistent with those reports of higher IL-6 in bone tissue cultures studies (25). In bone metabolism, the inflammatory cytokine TNF-α is one of the most potent osteoclastogenic cytokines. It stimulates synthesis of IL-6 in osteoblasts, and IL-6 functions to induce osteoclast formation and stimulate bone resorption (85). However, the mechanism behind TNF-α induced IL-6 synthesis in osteoblasts is unclear. Recently, data from cell culture experiments suggest that Wnt3a reduces TNF-α stimulated IL-6 release and expression via the Wnt pathway in
osteoblasts (61), suggesting a mechanistic role for Wnt signaling in the regulation of osteoclastogenesis. However, little is known about TNF-α mediated Wnt signaling in vivo or with mechanical loading. In the present study, thrice weekly high intensity exercise to the left leg was sufficient to prevent local bone loss but was unable to reduce systemic serum levels of IL-6. Taken together, these data suggest that suppressed Wnt signaling in just one unloaded limb may be sufficient to increase IL-6 release from bone cells and cause systemic levels of IL-6 to remain above normal. Alternatively, disuse may increase IL-6 production in other tissues (e.g., muscle) overshadowing any mitigation of disuse-induced IL-6 release from bone cells by SRT.

It remains to be determined if high resistance aRED exercises performed during 6-month ISS missions effectively mitigates microgravity-induced bone resorption. DEXA-derived measures of bone mass during ISS missions show that exercise performed on aRED, concurrent with improved nutrition intake, does mitigate much of the usually observed bone loss (76). Currently, NASA is testing the efficacy of an anti-resorptive bisphosphonate (alendronate) in preventing microgravity-induced bone loss. However, it is not clear how alendronate administration combined with exercise will impact on bone maintenance during space flight. The rate and amount of bone loss that occurs over the course of 6-month ISS missions is highly variable, similar to that observed in the general earth-bound population. Animal studies do demonstrate that alendronate can hinder exercised-induced gains in cancellous and cortical BFR (50,84). Future investigations may show if this high variability in bone loss also applies to a high variability in the response to exercise or drug interventions.
A limitation of the present study is that the GSK3 inhibitor we used does not discriminate between the inhibition of the alpha and beta forms, both of which are involved in modulating β-catenin levels (64). However, since these isoforms can compensate for each others’ reduced activity and maintain β-catenin levels, use of BIO in the present study, an inhibitor of both alpha and beta forms, almost certainly affected β-catenin levels. Future studies using more selective inhibitors of GSK-3 alpha or beta may allow determination of the relative impact of those specific isoforms on osteoblastogenesis and maintenance of bone mass during disuse.

In conclusion, we find that combining GSK-3 inhibition with high intensity exercise mitigates cancellous bone loss and restores cortical periosteal growth during disuse. Future studies are warranted to better understand how combined pharmacological activation of Wnt signaling (with more specific Wnt signaling drugs) and mechanical loading of bone can prevent bone loss.
CHAPTER V
CONCLUSIONS

The data presented here-in demonstrate that thrice weekly simulated resistance exercise can restore disuse-suppressed cortical bone formation and normalize the number sclerostin positive osteocytes. Secondly, the data show that simulated GCR (with low dose high LET radiation exposure) causes significant decrements in cancellous and cortical bone mass. In addition, this simulated GCR appears to exacerbate partial weightbearing-induced cancellous bone loss. Interestingly, fractionating low dose high-LET radiation does not protect against cancellous bone loss as was observed with fractionation of low dose low-LET radiation. Cortical bone in rats exposed to partial weightbearing conditions exhibits higher levels of sclerostin-positive osteocytes compared to full weightbearing controls. Unexpectedly, however, reduced weightbearing with added radiation exposure results in a greater number of sclerostin-positive osteocytes than with either treatment alone. In addition, simulated resistance exercise combined with GSK-3 inhibition shows added gains in cortical and cancellous bone mass compared to a single exercise or drug treatment alone. Taken together, these data suggest that regular high intensity resistance exercise may be an effective strategy to mitigate bone loss observed during long duration spaceflight or Lunar missions. Moreover, the data provide more evidence that Wnt signaling is highly responsive to mechanical loading conditions in cortical and cancellous bone.
REFERENCES


22. Foldes J, Shih M, Parfitt M. Frequency distributions of tetracycline-based measurements: Implications for the interpretation of bone formation indices in


79. Smith SM, Wastney ME, O’Brein KO, Morukov BV, Larina IM, Abrams SA, Davis-Street JE, Oganov V, Shackelford LC. Bone markers, calcium metabolism,


APPENDIX A*

HIGHLIGHTED TOPIC1 Physiology and Pathophysiology of Physical Inactivity

Simulated resistance training, but not alendronate, increases cortical bone formation and suppresses sclerostin during disuse

R. R. Macian,1 J. M. Swift,1 M. I. Nilsson,1 H. A. Hogan,2,3 S. D. Bonis,2 and S. A. Bloemfield1,4

Departments of 1Health and Kinesiology, 2Mechanical Engineering, 3Biomedical Engineering, and 4Intercollegiate Faculty of Nutrition, Texas A&M University. College Station, Texas

Accepted 5 August 2011; accepted in final form 13 December 2011

Macian BR, Swift JM, Nilsson MI, Hogan HA, Bonis SD, Bloemfield SA. Simulated resistance training, but not alendronate, increases cortical bone formation and suppresses sclerostin during disuse. J Appl Physiol 112: 918–925, 2012. First published December 15, 2011. doi:10.1152/japplphysiol.00978.2011—Mechanical loading modulates the osteocyte-derived protein sclerostin, a potent inhibitor of bone formation. We hypothesized that simulated resistance training (SRT), combined with alendronate (ALEN) treatment, during hindlimb unloading (HUL) would most effectively mitigate disuse-induced reductions in cortical bone geometry and formation rate (BFR). Thirty male, Sprague-Dawley rats (6–11 wk old) were randomly assigned to either cage control (CC), HUL + + ALLEN (HUL + ALLEN), or ALT + SRT (HUL + SRT) groups for 28 days. Computed tomography scans on days 1 and 28 were taken at the middiaphyseal tibia. HUL + SRT and HUL + ALLEN rats were subjected to muscle contractions once every 3 days during HUL (4 sets of 5 repetitions; 1,000 m isometric + 1,000 m eccentric). The HUL + ALLEN and HUL + SRT/ALLEN rats received 10 µg/kg ALLEN 3 times/wk. Compared with the CC animals, HUL suppressed the normal slow-growth-induced increases of cortical bone mineral content, cortical bone area, and polar cross-sectional moment of inertia; however, SRT during HUL restored cortical bone growth. HUL suppressed multiphysiological tibia periodontal BFR by 50% vs. CC (P < 0.05); however, SRT during HUL restored BFR at both periodontal (to 2.6-fold higher than CC) and endocortical (14-fold higher than CC) surfaces (P < 0.05). ALLEN attenuated the SRT-induced BFR gain during HUL. The proportion of sclerostin-positive osteocytes in cortical bone was significantly higher (+121% vs. CC) in the HUL group; SRT during HUL effectively suppressed the higher proportion of sclerostin-positive osteocytes. In conclusion, a majority number of high-intensity muscle contractions, performed during disuse, restores cortical BFR and suppresses unloading-induced increases in sclerostin-positive osteocytes.

Address for reprint requests and other correspondence: Susan A. Bloemfield, Dept. of Health and Kinesiology, MS 4243, Texas A&M Univ., College Station, TX 77843-4243 (e-mail: sbloemfi@tamu.edu).

*American Physiological Society permits whole published articles to be reproduced without charge in dissertations, which may be posted to theses repositories.
torque (P), produced during stimulated resistance training (SRT) undertaken during a period of HI produced significant gains in handgrip strength (BMD) and cortical bone mineral density (BMD). These gains were associated with a fivefold greater periosteal bone formation rate (BFR) compared with control animals (32). Numerous studies have investigated the efficacy of a pharmacological treatment [alendronate (ALEN)] in inhibiting disease-induced bone loss or in models of estrogen deficiency (1, 2, 28, 29). Bisphosphonate therapies potentially suppress accelerated osteoclast-mediated bone resorption. Currently, ALEN, an anti-resorptive bisphosphonate, is being administered to some asthmatics to improve lung function (33). The present intervention demonstrated that bisphosphonate treatment, when combined with moderate-intensity muscle contractions (75% P2) during disease, significantly increases proximal tibia total BMC (33). However, this combined drug/exercise countermeasure attenuates the cancellous bone formation response compared with the exercise-only group (33). The cellular mechanism by which SRT restores bone gain during unloading and how bisphosphonate treatment impacts the anabolic response of cortical bone to SRT remains undefined. To our knowledge, these are the first studies to employ a resistive exercise modality during HI with bisphosphonate treatment. The aim of this present investigation was to test the anabolic effects of SRT in combination with the anti-resorptive effects of ALEN during 28 days of HI in adult rats on disease-induced cortical bone decrements. We hypothesized that SRT, in combination with ALEN therapy during HI, would better mitigate deleterious changes in cortical bone mass, cortical bone geometry, cortical BFR, and that SRT but not ALEN would mitigate elevations of sclerostin-positive osteocytes.

MATERIALS AND METHODS

Animals and experimental design. Sixty male Sprague-Dawley rats were obtained from Harlan (Houston, TX) at 6 mo of age and allowed to acclimate for 14 days before initiation of the study. All animals were singly housed after arriving at our animal facility in a temperature-controlled (23 ± 2°C) room with a 12:12-h light-dark cycle in an American Association for Accreditation of Laboratory Animal Care-acknowledged animal animal care facility and were provided standard rodent chow (Harlan Teklad 8641) and water ad libitum. Animal care and all experimental procedures described in this investigation were approved by the Texas A&M University Laboratory Animal Care Committee. Previously, tissues from these same animals were utilized to assess the impact of ALEN and SRT on cancellous bone (34).

Five experimental groups were studied: 1) age-matched control (CC, n = 12); 2) HI (n = 12); 3) HI + ALEN (n = 12); 4) HI subjected to SRT (HI + SRT, n = 12); and 5) HI + ALEN+SRT animals underwent nine sessions of simulated resistive exercise conducted on every 3 days during the 28-day protocol. The HI and HI + ALEN groups were also subjected to SRT and HI + ALEN+SRT animals underwent nine sessions of simulated resistive exercise conducted on every 3 days during the 28-day protocol. The HI and HI + ALEN groups were also subjected to SRT and HI + ALEN+SRT animals underwent nine sessions of simulated resistive exercise conducted on every 3 days during the 28-day protocol. The HI and HI + ALEN groups were also subjected to SRT and HI + ALEN+SRT animals underwent nine sessions of simulated resistive exercise conducted on every 3 days during the 28-day protocol.

Voltage optimization to achieve V2 and stimulation frequency optimization of the eccentric torque were performed at the beginning of each session, as described previously (32). The eccentric phase of the muscle contraction was sustained for 75% of each animal’s daily V2. The HI+SRT and HI+SRT+ALEN animals completed a 20-s isometric + eccentric SRT exercise paradigm, consisting of four sets of five repetitions, once every 3 days during HI (n = 9 total exercise sessions). The training paradigm consisted of a 1,000 ms isometric contraction (75%), immediately followed by a 1,000-ms eccentric contraction (75% of the peak isometric contraction).

Bisphosphonate treatment. Animals in the HI + ALEN and HI + SRT+ALEN groups were administered 10 μg ALEN (Merck and Co.) and 50 μg ALEN (Merck and Co.) via subcutaneous injection 3 times/wk for the duration of the 28-day study. The ALEN dose of 30 mg/kg body mass (P) was the lowest dose (of three tested) that effectively mitigated reductions in cancellous volumetric BMD at the proximal tibia during 28 days of HI (unpublished data) and is similar to the 30 μg/kg ALEN (5 μg/kg, 2 times/wk) shown to maintain femur and lumbar spine bone mass and strength after ovariohysterectomy (OVX) in rats (10). This ALEN dose of 10 μg/g body mass (P) was used in previously published clinical studies and in OVX rats, demonstrating pronounced increases in bone mass and strength (19). Rats in the CC, HI, and HI + SRT groups were administered an equal volume of vehicle (phosphate-buffered saline) by subcutaneous injection 3 times/wk.
Peripheral QCT. On days 1 and 28 of the study, peripheral QCT (pQCT) scans were performed in vivo on the tibia middiaphysis with a Stratec XCT Research device (Norland, Fort Atkinson, WI), using a voxel size of 100 μm and a scanning beam thickness of 500 μm. Two slices centered at 50% of the tibial total length (determined from a scout view on the CT scanner) were collected. Calibration of this machine was performed on each day of scanning with a hydroxyapatite-stained cross phantom. A standardized analysis for diaphyseal bone (contour mode 1, peak mode 2, outer threshold of 0.650 g/cm², inner threshold of 0 g/cm²) was applied to each section.

Values of cortical BMC, cortical bone area, and the polar cross-sectional moment of inertia (CSMI) were averaged across the two slices at the tibial middiaphysis to yield a mean value. Polar CSMI was based on geometry only and not weighted by density. Machine precision (based on manufacturer's data) is ±9 μm² for cortical bone. Reproducibility in our laboratory was determined from five repeat scans using an in vivo multiple-slice scanning method; resulting coefficients of variation for cortical tibia BMC was ±0.99%.

Dynamic histomorphometry analysis. Unmineralized distal tibia slices were subjected to serial dehydration and embedded in methylmethacrylate (Sigma-Aldrich M5, 505-9). Sts. Morris, MO). Serial cross sections (150-200 μm) of midshaft cortical bone were cut starting 2.5 mm proximal to the tibial epiphysis with an Isomet diamond wafer low-speed saw (Buehler, Lake Bluff, IL). Sections were ground to reduce thickness (<80 μm) before mounting on glass slides. The histomorphometric analyses were performed using the OsteoMeasure Analysis System, version 1.3 (OsteoMetrics, Atlanta, GA). Measurements of labeled surfaces and interlabeled widths were obtained at ×100 magnification of up to two slides per animal. Periosteal and endocortical mineral apposition rates (MAR, μm/day) were calculated by dividing the average interlabeled width by the time between-labels (7 days) and interlabeled widths (μm) for both periosteal and endocortical bone surfaces (BS) by the formula: MAR = BS/SBS/7 = [(single-labeled surface/2) + double-labeled surface/2] / (surface perimeter) × 100. BFR was calculated as MAR × BS/BS.

Sclerosis immunostainchemistry. Distal tibia femora were fixed in 4% phosphate-buffered formalin for 48 h at 4°C, then decalcified in a sodium citrate-formic acid solution for 14 days, and stored in 70% ethanol. Following decalcification, the distal tibia femora were embedded in paraffin, and transverse sections at the midshaft were cut 10 μm thick and mounted on slides. Five slides, one slide from each group, were placed in a dry incubator at 60°C for 15 min to melt the paraffin. Slides were then washed in 70, 95, 100, and 100% ethanolic solution for 3 min each. Slides were then washed in xylene twice for 5 min each. To quench endogenous hydrogen peroxide that may interfere with the horseradish peroxidase reaction, slides were soaked in 0.3% hydrogen peroxide solution for 30 min. A hydrophobic permeator was drawn around the tissue to maintain small-volume solutions above the tissue sample during incubation. Slides were washed twice in PBS for 5 min each, and then slides were washed in PBS/0.5% Triton solution for 5 min. Slides were washed twice in PBS for 5 min each. Tissues were blocked with normal goat serum for 20 min, followed by a 5 min wash in PBS/0.5% normal goat serum solution. To reduce nonspecific binding, the tissue sections were treated with the avidin/biotin blocking kit per manufacturer's instructions (SP-2001, Vector Laboratories, Burlingame, CA), followed by these 5 min washes with PBS. Tissues were then placed on a wet-implementation tray, and each sample was loaded with the sclerostin primary antibody (1:250 dilution, R&D Systems, Minneapolis, MN) and incubated at 4°C overnight. Following overnight incubation, tissues were washed twice with a PBS/0.1% BSA/0.2% Tween solution, then washed twice with a PBS/0.2% BSA/0.1% Tween solution, then washed twice with a PBS/0.2% BSA/0.1% Tween solution. The tissue sections were incubated in secondary antibody solution and incubated for 30 min (Vectorshield Elite ABC Kit, Vector Laboratories, Burlingame, CA), Tissue was developed with diaminobenzidine substrate solution (Norsat/BD, Vector Laboratories, Burlingame, CA) for 10 min to stain sclerostin-positive osteocytes. Slides were washed quickly in PBS to terminate the reaction, taped dry, counterstained with hematoxylin, dehydrated, cleared, and allowed to dry in the dark for 2 days. The section was then scanned using a Nikon CoolScan microdensitometer (Nikon, Tokyo, Japan) at 300 dpi resolution.

Statistical analysis. All data are expressed as means ± SE and evaluated using the statistical package SPSS (version 15.0 Chicago, IL). Histomorphometry and sclerosis assays were first analyzed using a two-factor ANOVA (exercise and ALEN) to compare group differences between HU groups (HU, HU+ALLEN, HU+SRT, and HU+SRT/ALLEN). A Tukey's post hoc test was used for pairwise comparisons. Subsequently, a one-factor ANOVA was employed to determine significant longitudinal pQCT variables changes within each treatment group (in vivo pQCT data only). For all data, statistical significance was accepted at P < 0.05.

RESULTS

SRT during exercise restored normal age-related cortical bone mass. HU for 28 days suppressed the normal growth gains in cortical BMC by 72%, compared with CC. The lack of BMC accrual in the HU+ALLEN rodents (-0.44% change over 28 days) was similar to the HU-alone group (0.48%). However, when SRT was prescribed during 28 days of HU, normal growth gains in cortical BMC were restored (Table 1). ALEN administration did not appear to negatively affect the restoration of BMC by the mice trained by SRT (HU+SRT/ALLEN group). The magnitude of changes in cortical area at the tibial middiaphysis was similar to those of changes in BMC. The SRT exercise provided a potent mechanical stimulus to restore the normal growth gains during the cortical shell in both the HU+ SRT (7.88%) and HU+SRT/ALLEN (5.90%) groups, comparable to the gain in cortical area of the CC (5.61%) group. As expected, there was essentially no change in cortical bone area in the HU group. ALEN administration during HU did not rescue gains in cortical bone area and actually resulted in a slight reduction (-2.25%, P = 0.079). The increase in cortical bone area was accompanied by increased polar CSMI in the CC (14%), HU+ SRT (13%), and HU+SRT/ALLEN (10%) groups. Polar CSMI was significantly reduced in the HU+ALLEN group by 5%. A similar decrease (-3%) was noted in the HU group; however, this change was not statistically significant. An increase in cortical volumetric BMD (0.3 to 1.8%) was observed among the groups; however, this change was not statistically significant.

ALEN blunts the cortical bone formation response to SRT during exercise. Markers of osteoclast activity on the periosteal surface of the tibia middiaphysis were substantially lower in the HU group vs. those in the CC group. These animals given ALEN during HU show the lowest BFR, compared with all other groups. The application of SRT during HU produced significantly higher BFR on the periosteal surface at the tibia diaphysis (Fig. 1). The HU+SRT group demonstrated an eightfold higher BFR compared with HU. Moreover, when SRT was prescribed alone or in combination with ALEN treatment during HU, periosteal BS/BS was significantly higher than CC (+50% and 19%), HU (+13% and 109%), and HU+ALLEN (+10-fold greater) groups. Periosteal MAR was lower in the HU+SRT/ALLEN compared with HU+SRT; how-
Table 1. SRT during disuse normalized cortical BMC, cortical area, and polar CSMI

<table>
<thead>
<tr>
<th></th>
<th>CC</th>
<th>HU</th>
<th>HU+ALLEN</th>
<th>HU+SRT</th>
<th>HU+SRT+ALLEN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortical BMC mg</td>
<td>8.08 ± 0.15</td>
<td>8.30 ± 0.22</td>
<td>8.19 ± 0.13</td>
<td>7.81 ± 0.16</td>
<td>8.14 ± 0.13</td>
</tr>
<tr>
<td>Day 0</td>
<td>8.52 ± 0.14^*</td>
<td>8.43 ± 0.20^*</td>
<td>8.07 ± 0.13^*</td>
<td>8.25 ± 0.16^*</td>
<td>8.08 ± 0.15^*</td>
</tr>
<tr>
<td>%Change</td>
<td>0.04</td>
<td>0.08</td>
<td>0.06</td>
<td>0.05</td>
<td>0.06</td>
</tr>
<tr>
<td>Cortical area, mm²</td>
<td>6.14 ± 0.11</td>
<td>6.32 ± 0.17</td>
<td>6.29 ± 0.11</td>
<td>5.96 ± 0.12</td>
<td>6.21 ± 0.10</td>
</tr>
<tr>
<td>Day 0</td>
<td>6.48 ± 0.11^*</td>
<td>6.50 ± 0.15^*</td>
<td>6.05 ± 0.10^*</td>
<td>6.42 ± 0.12^*</td>
<td>6.44 ± 0.14^*</td>
</tr>
<tr>
<td>%Change</td>
<td>0.04</td>
<td>0.08</td>
<td>0.06</td>
<td>0.05</td>
<td>0.06</td>
</tr>
<tr>
<td>CSMI, mm²</td>
<td>12.48 ± 0.57</td>
<td>13.58 ± 0.03</td>
<td>12.74 ± 0.56</td>
<td>12.96 ± 0.48</td>
<td>13.64 ± 0.58</td>
</tr>
<tr>
<td>Day 0</td>
<td>14.22 ± 0.57^*</td>
<td>13.58 ± 0.79^*</td>
<td>11.77 ± 0.20^*</td>
<td>13.81 ± 0.52^*</td>
<td>13.74 ± 0.63^*</td>
</tr>
<tr>
<td>%Change</td>
<td>0.04</td>
<td>0.08</td>
<td>0.06</td>
<td>0.05</td>
<td>0.06</td>
</tr>
</tbody>
</table>

Values are group mean ± SE. Hindlimb unloading (HU) suppressed change in bone mineral content (BMC), cortical area, and polar cross-sectional moment of inertia (CSMI). Unexpectedly however, simulated resistance training (SRT) was a potent stimulant during HU, effectively restoring cortical bone geometric properties. *P < 0.05 vs. prevalue. #H-U groups not sharing the same letter for respective measures are significantly different from each other (P < 0.05).

ever, MAR of the HU+SRT/ALLEN group remained nearly twofold higher than that of CC and HU.

Mechanical loading paradigms typically do not show robust bone formation effects at the endocortical surface. However, when SRT was prescribed alone or in combination with ALLEN treatment during HU, endocortical MS/B/S was significantly higher than CC (+270% and +220%), HU (+280% and +440%), and HU+ALLEN (+28–40-fold greater) groups (Fig. 1). SRT

![Fig. 1. Effects of hindlimb unloading (HU), with or without alendronate (ALLEN) treatment and/or simulated resistance training (SRT), on periosteal and endocortical surface dynamic histomorphometric analyses measured at the tibia diaphysis. A: mineralizing surface (SMS)/bone surface (BS). MAR: mineral apposition rate (MAR). C: bone formation rate (BFR). Vertical dashed line indicates separation of cage control (CC) from the experimental groups for pullulan ANOVA. Values are means ± SE. *a,b,#H-U groups not sharing the same letter for respective surface measures are significantly different from each other (P < 0.05). *Significantly different vs. CC (P < 0.05).](https://jappi.org)
BISPHOSPHONATES AND EXERCISE DURING DISUSE

alone or in combination with ALEN administration during HU show significantly higher MAR and BFR at the endocortical surface. As expected, the BFR in the HU+ALEN was maximally suppressed and significantly lower than all other groups. The endocortical-BFR was significantly higher in the HU+SRT/ALEN group compared with CC (+7-fold), HU (+17-fold), and HU+ALEN (+167-fold); however, it was significantly less than the HU+SRT group (−56%). ALEN did dampen the robust endocortical bone formation (MS/BS, MAR, and IhvO) to SRT during HU; however, HU+SRT/ALEN was not significantly less than the HU+SRT group. The impaired bone formation by ALEN administration can be seen visually by narrower widths of calcin labeling on the periosteal and endocortical surfaces when comparing the HU+SRT/ALEN with HU+SRT groups (Fig. 3).

The proportion of sclerostin-positive cortical osteocytes is suppressed by muscle contractions, but not ALEN treatment. Complete unloading of the hindlimb in the HU animals resulted in a significantly higher number of sclerostin-positive osteocytes vs. that observed in weight-bearing CC animals. ALEN treatment of HU animals had no effect on the proportion of sclerostin-positive osteocytes. By contrast, both groups subjected to SRT during unloading exhibited much lower prevalence of sclerostin-positive osteocytes, close to CC rat values (Fig. 3).

DISCUSSION

Our major finding in these studies was that ALEN treatment blunted the BFR response to SRT during rodent HU. Our data did not support our hypothesis that the combination of ALEN and resistance exercise therapies would better ameliorate deleterious changes in cortical bone than with ALEN or SRT administration alone.

Previously, we demonstrated that a similar simulated resistive exercise training paradigm with isometric and eccentric components (both at 100% peak isometric strength) effectively mitigates losses in muscle strength and provides a potent stimulus to bone during prolonged disuse (32). In the present study, a similar resistance exercise paradigm was utilized; however, the force of contractions, isometric and eccentric components, was titrated down to 75% of peak isometric strength. Even with this 25% reduction in muscle contraction intensity, this exercise modality elicited a robust bone formation response and restoration of normal bone accrual during a period of disuse. The gains in midshaft cortical BMC and in cortical area with the reduced intensity protocol were only slightly smaller than those observed with the previous higher intensity regimen; the gain in polar CSMI, a key predictor of bending strength, was identical in both protocols. Furthermore, the prescription of SRT at 100% P0 or 75% P0 during HU elicits a similar periosteal and endocortical bone forming response (as measured by MS/BS, MAR, and BFR) of cortical bone. Interestingly, visual inspection of the data appear to show more single and double labeling at the posterior-lateral and anterior-medial surfaces than other cortical bone surfaces of the tibia. Taken together, these data suggest that a 25% reduction in SRT intensity may not elicit a proportional reduction in the positive responses observed in bone geometry and bone formation in the context of disuse. Using a training intensity commonly used by humans performing resistance training programs, the present training regimen effectively prevented the suppression of cortical bone gain observed with unloading.

ALEN treatment given during HU produced significant further reductions in actively mineralizing surfaces (%MS/BS) and MAR beyond that observed with unloading alone, suggesting that ALEN treatment reduces both the number of remodeling sites and vigor of the individual osteoblast units (2). When given to animals also receiving infrequent bouts of SRT during HU, ALEN attenuated the cortical bone formation response primarily via a blunting of MAR without any significant impact on %MS/BS. Interestingly, when another common bisphosphonate, risedronate, is administered along with mechanical loading of mouse tibiae, no negative effects are observed in cortical geometric bone gains (31), consistent with the present data that ALEN and mechanical loading can exert independent effects. It is highly likely that the decreased bone formation observed at the periosteal surfaces with ALEN treatment at 28 days of HU would eventually impact on cross-sectional geometry, and/or local BMC were the period of disuse prolonged, resulting in changes in bone density and mechanical properties that could not be detected with the present study’s limited time frame.

In general, cancellous bone is more responsive to disuse than is cortical bone, exhibiting more rapid declines in bone formation activity and in bone volume (4). Even so, we observed that cortical bone formation was significantly impaired on the periosteal surface during 28 days of HU, contributing to an

![Fig. 2: Visual depiction (X1000 magnification) of calcin labeling of the periosteal and endocortical surface of cortical bone at the tibia diaphysis. Note the extensive fluorescence labeling in CC, HU, HU+SRT, and HU+SRT/ALLEN and large interlabel width (HU+SRT and HU+SRT/ALLEN).](J Appl Physiol - doi:10.1152/japplphysiol.00978.2011 - www.jappl.org)
inhibition of the slow midshaft cortical bone growth observed in these male rats. This adaptation of cortical bone is consistent with previous studies of space-flown and HU-Rats that document a reduction in radial bone growth and bone strength (20, 21). In the present study, cortical BFR in unloaded animals was further suppressed by ALEN administration, which contrasts with our laboratory’s previous observations of no additional effect of ALEN administration on disease-induced reductions on cancellous BFR in the proximal tibia (33). The major impact of disease on osteoblast activity in the cancellous compartment may have occurred early in the 28-day unloading period, whereas the slower response of cortical bone to disease enabled the present study to detect ALEN effects on bone formation within the same period. However, when ALEN was given to HU animals experiencing intermittent mechanical loading (HU+SRT/ALLEN), the resulting robust increases in bone formation were impaired at both cortical and cancellous (33) bone sites, as measured over the last 9 days of the experiment.

Bisphosphonates may directly affect osteoblast precursors and osteoblast activity. For example, Gasser et al. (11) demonstrated that ALEN administration before PTH administration reduces MAR, possibly by blunting the bone-lining cell transition to osteoblast. In addition, resorptive treatment causes osteoblasts to adopt a flatter cell morphology, a reminiscent cell shape of bone-lining cells, suggesting that resorptive retards normal osteoblast activity (22). Therefore, the present study demonstrated that ALEN blunting of BFR on the peristichal surface is consistent with previous reports that ALEN may have direct effect on osteoblast precursor cells and activity.

There are data to suggest that exercise, in combination with anti-resorptive compounds, provides additive, and perhaps synergistic, benefits to bone mass and strength. More data are available testing bisphosphonates’ impact on bone loss subsequent to estrogen deficiency and less documenting effects of exercise during disease. For example, eridionate treatment and treadmill exercise show significantly higher BMC at the midshaft femur in an OVX rat bone loss model (34). Similarly, OVX rats treated with ALEN and treadmill exercise therapy show higher midshaft femur BMC and cortical thickness (35). Therefore, at bone sites, combined bisphosphonate and exercise therapy show added and perhaps synergistic effects at cortical bone sites. However, zoledronic acid and treadmill exercise therapy of OVX rats show no additive effect on cortical BMC or BMD (18). In addition, when OVX rats are exposed to both external mechanical loading of the tibia and ALEN treatment, the bone formation response to mechanical loading is not impaired (7). Conversely, ALEN given to rapidly growing young rats during HU inhibits cortical BFR and MAR at the tibia diaphysis by ~15% (3). A more mature (50 g) rat treated with ALEN during HU, but without exercise, shows higher cortical BMC (tibia and femur) compared with vehicle-treated animals (2). Collectively, these data suggest that certain bisphosphonate treatments, when given to an ambulatory fullweight-bearing rat, may prevent OX-induced bone loss. However, in the context of reduced weight bearing, bisphosphonates may attenuate the bone formation response to mechanical loading.

The Wnt pathway coordinates communication between mechanosensing osteocytes (via secreted sclerostin) and bone-forming osteoblasts by the binding of sclerostin to lipoprotein
receptor-related protein (Lrp) 4/5/6 (6, 9, 39). Loss-of-function mutation of the Lrp5 gene results in decreases in bone mass and bone strength (13). Receptor-mediated interaction of Wnt proteins with Lrp4/5/6 receptors, effectively reducing Wnt signal transduction and resulting osteogenesis (23). Recently, mechanical loading in vivo downregulates sclerostin-positive osteocytes, the gene SOST, and upregulates osteogenic expression (26). Moreover, when sclerostin-null mice are subjected to simulated microgravity, the Wnt pathway and bone loss does not occur (35). Therefore, the reduced increase of sclerostin-positive osteocytes during disuse observed in the present study is consistent with previous work demonstrating higher Scr transcript levels at day 7 of 11U and reduced numbers of sclerostin-positive osteocytes after 2 days of unloading (without muscle contraction) (36).

In the present investigation, ALIN treatment did not significantly affect the number of sclerostin-positive osteocytes. Although ALIN is effective in preventing osteocyte apoptosis (23, 24, 33), it does not appear to alter the mechanotransduction function of osteocytes to lead or the proportion of sclerostin-positive osteocytes. This finding suggests that the modulation of osteoclast activity and apoptosis by ALIN may be independent of sclerostin control.

In conclusion, the present study demonstrates that moderate-intensity, low-volume loading of bone by active muscle contraction during a period of imposed disuse reduces sclerostin-positive osteocytes, coincident with increased bone formation activity to levels higher than those observed in weight-bearing control animals. These data extend previous work utilizing the SPT paradigm (low-volume/high-intensity exercise via physiological muscle contraction), which mitigates cancellous bone loss and prevents suppression of mechanical and physical peristalsis during unloading (1). Future studies should investigate the intracortical signaling pathway responsible for the attenuation of the bone formation response to SPT by ALIN given during IUH. In addition, the inclusion of a weight-bearing recovery component to the present study may help elucidate if bisphosphonate treatment impairs long-term bone formation capability.

ACKNOWLEDGMENTS

The authors gratefully acknowledge Janet Stillman for assistance with animal care, and Dr. Gordon Warren (George State University) and Ken Baldwin (University of California, Irvine) for assistance with the simulated microgravity protocol and procedures. Alumina boxes were generously provided by Merck Pharmaceuticals.

Present address of J. M. Swift: Radiation Combined Injury Program, Armed Forces Radiobiology Research Institute, Uniformed Services University of the Health Sciences, Bethesda, MD 20889-5903.

GRANTS

These studies were funded through the National Aeronautics and Space Administration Cooperative Agreement NCC 9-50 with the National Space Biomedical Research Institute (S. A. Bloomfield), B. R. Macias and J. M. Swift were supported by National Space Biomedical Research Institute Graduate Training Fellowship NSBR-IERT-05-02. B. R. Macias is a National Science Foundation Graduate Research Fellow.

DISCLAIMER

The views, opinions, and findings contained herein are those of the author J. M. Swift and do not necessarily reflect official policy or positions of the Department of the Navy, Department of Defense, or the United States Government.
BIPHOSPHONATES AND EXERCISE DURING DISUSE